2 THANK YOU TO OUR SPONSORS THANK YOU TO OUR SUPPORTING PARTNERS Co-Sponsors
1 Welcome to BioNJ’s 2023 BioPartnering Conference, On behalf of BioNJ, J.P. Morgan, Johnson & Johnson Innovation and Morgan Lewis, it is our honor to welcome you to the Thirteen Annual BioPartnering Conference, “Partnering for Possibility.” We are excited to bring together life sciences executives, investors, academic collaborators and business development professionals from the Northeast and beyond for networking, 1-1 partnering (including in-person on the day of the Conference and virtual partnering throughout the rest of the week), a record number of company and start-up pitches, exhibits and plenary sessions. The action-packed schedule is designed to foster productive partnerships, create meaningful opportunities, grow the ecosystem and bolster medical innovation. There are many people to thank for their contributions in getting us to this important day, beginning with our speakers, judges, reviewers, exhibitors, supporting partners and generous sponsors who have supported this initiative in exceptional ways. We are grateful to our industry experts who are leading the plenary discussions. Additionally, we are appreciative of the world-renowned regional institutions exhibiting, reminding us of the critical role industry and academic collaboration plays in driving innovation. And finally, a special thank you to the BioPartnering Conference Planning Team Members who have given so generously of their time and talent during the last several months to transform a vision from concept to reality. We hope you come away from the Conference with new collaborations, partnerships and inspiration that will lead to future innovation. Thank you for being here. Because Patients Can’t® Wait WELCOME Debbie Hart President & CEO BioNJ David C. Schwartz Partner Morgan, Lewis & Bockius LLP Samuele Butera President, US Pulmonary Hypertension & Retina The Janssen Pharmaceutical Companies of Johnson & Johnson Co-Sponsors Kathleen Addison Executive Director Life Sciences J.P. Morgan
2 CONFERENCE AGENDA Tuesday, April 18, 2023 7:30 a.m. – 8:10 a.m. REGISTRATION & NETWORKING BREAKFAST 7:30 a.m. – 8:30 a.m. PARTNERING AVAILABLE 8:15 a.m. – 8:30 a.m. WELCOME & OPENING REMARKS • Debbie Hart, President & CEO, BioNJ • Samuele Butera, MPP, President, US Pulmonary Hypertension and Retina, The Janssen Pharmaceutical Companies of Johnson & Johnson • Steve Cohen, JD, MBA, Partner & Chair, Emerging Business & Technology Practice, Morgan Lewis • Kristine O’Keefe, CFA, CFP, Executive Director, J.P. Morgan Private Bank 8:30 a.m. – 9:00 a.m. BIOTECH INDUSTRY OVERVIEW: STATS, TRENDS & LAY OF THE LAND • Phil Ross, M.D., MBA, Global Chair, Investment Banking, J.P. Morgan 9:00 a.m. – 9:40 a.m. PANEL: PARTNERING & RAISING CAPITAL – BEST PRACTICES IN RECOVERING BIOTECH SECTOR Panelists: • Sal Giovine, MBA, Chief Financial Officer, Pharmaceutical BD & External Innovation, Johnson & Johnson • Eric Heil, MBA, Managing Partner, Medical Excellence Capital • Alan Leeds, JD, Partner, Life Sciences Transactions Practice Leader, Morgan Lewis • Ivor Macleod, Chief Financial Officer, SCYNEXIS Moderator: Chris Gartin, Managing Director, Healthcare Investment Banking, J.P. Morgan 9:40 a.m. – 10:10 a.m. BUILDING A WORKFORCE FOR BIOPHARMA MANUFACTURING Panelists: • Aaron R. Fichtner, Ph.D., MCRP, President, New Jersey Council of County Colleges • Kara Moore, MIS, Senior Advisor, Sector Development, New Jersey Economic Development Authority • Kristy Shuda McGuire, M.S., Ph.D., Dean, Biomedical Studies, The Wistar Institute Moderator: Bob Bowden, Ph.D., Senior Director, CAR-T Manufacturing, Janssen Pharmaceuticals 10:10 a.m. – 10:20 a.m. NETWORKING BREAK: VISIT EXHIBITS & INSTITUTION ALLEY 10:20 a.m. – 11:50 a.m. COMPANY PITCH PRESENTATIONS 10:30 a.m. – 12:00 p.m. PARTNERING AVAILABLE Co-Sponsors
3 CONFERENCE AGENDA 12:00 p.m. – 1:00 p.m. NETWORKING LUNCHEON Featuring a Fireside Chat with Dana Callow, MBA, Managing Partner, Boston Millennia Partners Interviewer: Andrew M. Evens, DO, MBA, MSc, Assoc. Vice Chancellor, Clinical Innovation & Data Analytics, Rutgers Biomedical & Health Sciences; Assoc. Director (Clinical Services), Rutgers Cancer Institute of New Jersey; System Director, Medical Oncology & Oncology Lead, RWJBarnabas-Rutgers Medical Group, RWJBarnabas Health & Professor, Medicine, Rutgers Robert Wood Johnson Medical School Plus, remarks by BioNJ Chair Amadou Diarra, Ph.D., Senior Vice President, Global Policy, Advocacy & Government Affairs, Bristol Myers Squibb 1:30 p.m. – 5:30 p.m. PARTNERING AVAILABLE 1:05 p.m. – 1:45 p.m. CONCURRENT BREAKOUT SESSIONS: Panel: Health Equity in Clinical Trials School Teams Presenting: • Johns Hopkins University • Rutgers University • Baylor College of Medicine, Northwestern University & Rice University Moderator: Paul Howard, Ph.D., Senior Director, Public Policy, Amicus Therapeutics –––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Navigating the Journey from Start-Up to Commercialization: Avoiding “Oh No!” Moments Panelists: • Kathleen Addison, Executive Director, Life Sciences, J.P. Morgan • Nitin Khanna, CEO, Archer Insights • David Schwartz, JD, Partner, Morgan Lewis Moderator: Ravi Raghunathan, CPA, Partner, Life Sciences Leader, CohnReznick 1:55 p.m. – 2:30 p.m. CONCURRENT BREAKOUT SESSIONS: Panel: The Path to Successful Value Creation and Partnering with Higher Education Institutions and Academic Medical Centers Panelists: • Amit Bhalla, MPH, MBA, Chief Financial Officer, Sampled • Steve Brugger, Former CEO, Affinivax (Acquired by GSK) • Mike Poisel, MS, MBA, Executive Director, Penn Center for Innovation • John Ritter, JD, MBA, Director, Office of Technology Licensing, Princeton University • Ofra Weinberger, Ph.D., Director of Licensing, Columbia Tech Ventures; Associate VP, Tech Transfer & Intellectual Property, Columbia University, Columbia Tech Ventures Moderator: Mike Wiley, JD, MBA, Vice President, Foundation Venture, Capital Group –––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– A Whole New Day at the NJEDA and Beyond: Raising Capital via Government-Supported Programs Panelists: • Kathleen Coviello, MBA, Chief Economic Transformation Officer, New Jersey Economic Development Authority • Mahako Etta, Ph.D., MPA, Program Manager, New Jersey Commission on Science, Innovation and Technology • Rik Mehta, Pharm.D., JD, LL.M, CEO, Lactiga • Gina Tedesco, MBA, Managing Director, Golden Seeds Moderator: Taryn Bostjancic, CPA, CGMA, Partner, Life Science Services Practice Leader, Withum 2:30 p.m. – 2:45 p.m. REFRESHMENTS & NETWORKING IN THE EXHIBIT HALL 2:45 p.m. – 4:30 p.m. COMPANY PITCH PRESENTATIONS 4:30 p.m. – 5:45 p.m. COCKTAIL RECEPTION & AWARDS PRESENTATIONS
4 SPEAKERS Kathleen Addison Executive Director, Life Sciences J.P. Morgan Ms. Addison is a Life Sciences Banker in the Commercial Bank for J.P. Morgan covering the New Jersey Market. Her life sciences clients include U.S. based and multinational pharmaceutical, biotech, medical device, CRO, CMO, health tech and animal health companies. Ms. Addison’s role is to bring the unique and growing number of healthcare resources at J.P. Morgan to life sciences companies from start-up to fully commercialized. These resources include life science-specific treasury and asset management, credit support that grows with our life sciences companies, including M&A, ABL, commercial card, letters of credit and traditional lines of credit, connectivity with J.P. Morgan investment banking, our venture debt solutions and other recently announced J.P. Morgan healthcare initiatives. Amit Bhalla, M.P.H., MBA Chief Financial Officer Sampled Mr. Bhalla has more than 25 years of Wall Street and healthcare industry experience. His background in finance, strategy and business development includes experience in equity investing as well as sourcing, negotiating and integrating transformational and tuck-in M&A. Most recently he served as Senior Healthcare Analyst at Lord, Abbett & Co. with responsibility for investments across all healthcare verticals in seven Lord Abbett funds. His previous experience also includes Global Strategy & Business Development responsibility at Becton Dickinson where he sat on the Executive Management Committee. Prior to Becton Dickinson, Mr. Bhalla held senior roles at Citigroup, Morgan Stanley and Johnson & Johnson. Taryn Bostjancic, CPA, CGMA Partner, Life Science Services Practice Leader Withum Ms. Bostjancic is a Partner based in Withum’s East Brunswick, NJ office and serves as the Practice Leader for the firm’s Life Sciences Service Group. With over 25 years of public accounting experience, she has focused most of her career providing accounting, auditing and advisory services to private and public companies in the life sciences space. Ms. Bostjancic’s client base includes pharmaceutical, medical device, diagnostic, therapeutics and research companies. She was named NJBIZ’s “Forty Under 40” and “Best 50 Women in Business”, recognizing her for her commitment to business growth, professional excellence and involvement in the community. Bob Bowden, Ph.D Senior Director, CAR-T Manufacturing Janssen Pharmaceuticals Dr. Bowden supports Janssen’s CAR-T Manufacturing leading the CELL STARs talent acquisition and retention strategy program and serves as a technical SME with active commercial sites. He established the Global Cell Collection team, responsible for collection and cryopreservation of white blood cells for personalized multiple myeloma therapy. Initially at J&J, Dr. Bowden defined and conducted health outcome and social impact plans for access programs in limited resource settings. While in the U.S. Army for over 26 years, he investigated and led multi-national scientific teams to create life-saving vaccines and diagnostics from early pre-clinical stage to Phase III international trials. Dr. Bowden is an inventor, published author and former academic professor. Steve Brugger, MBA Former CEO Affinivax (Acquired by GSK) Mr. Brugger has over 40 years of experience in the biotechnology and pharmaceutical industries, currently serving as a consultant and advisor to several different companies. His most recent position was as a Founder and the CEO of Affinivax, Inc., where he led the building of the company from its initial inception in 2014 to its final acquisition by GSK in 2022. Under his leadership, Affinivax licensed in the technology from Boston Children’s Hospital, secured its initial funding from the Bill & Melinda Gates Foundation, completed a global commercial license agreement with Astellas Pharma for its lead vaccine program and closed two financing rounds raising $120M and $226M, respectively.
5 SPEAKERS Samuele Butera, MPP President, US Pulmonary Hypertension and Retina, President, The Janssen Pharmaceutical Companies of Johnson & Johnson As President of Pulmonary Hypertension and Retina Gene Therapies in the U.S., Mr. Butera is dedicated to supporting rare disease Patient populations and responsible for leading this therapeutic area through the continued advancement of key brands and preparing future pipeline launches. With a proven track record in delivering global healthcare innovation and business leadership, Mr. Butera’s goal is to bring transformational solutions to Patients, providers and healthcare systems around the world. Previously, Mr. Butera held global leadership roles at Janssen and Novartis, following international experiences at McKinsey & Company, Goldman Sachs and the United Nations. Dana Callow, MBA Managing Partner Boston Millennia Partners Prior to founding Boston Millennia Partners, Mr. Callow co-founded the predecessor fund of BMP in 1982. Before that, he worked as a Senior Consultant at Braxton Associates, an international strategic planning firm that was formed by professionals from Bain & Co. and Boston Consulting Group. Mr. Callow worked with Fortune 100 companies in strategic planning and implementing merger and acquisition strategies. Prior to working in the management consulting business, Mr. Callow worked in sales and marketing for Tymshare, Inc. (McDonnell-Douglas). He was formerly Lead Director and Chair of the governance committee of PAREXEL International Corporation, a $2.5 billion revenue clinical trials management company sold on September 29, 2017, for $5 billion. Steve Cohen, JD, MBA Partner and Chair, Emerging Business and Technology Practice Morgan Lewis Mr. Cohen represents entrepreneurs, private equity investors and venture capital funds. He advises clients in such industries as technology, life sciences, chemicals, consumer products, digital health and fintech. Mr. Cohen counsels mid-Atlantic region investors and emerging growth companies in a variety of business transactions, including equity financing transactions, mergers and acquisitions (M&A), divestitures, initial public offerings (IPOs), joint ventures and international strategic partnerships. With a knack for creating connections between investors and entrepreneurs, he helps develop and implement growth strategies, working with companies throughout their entire lifecycle. Mr. Cohen lectures frequently on planning profitable exit strategies, obtaining angel and venture capital financing for early stage companies and business leadership. Kathleen Coviello, MBA Chief Economic Transformation Officer New Jersey Economic Development Authority (NJEDA) Ms. Coviello oversees the Authority’s strategic sector, economic transformation products (corporate tax credit programs, clean energy and offshore wind products, innovation and venture products and strategic innovation centers) and the Product Operations departments. The Division provides value-added business engagement and products targeted at commercial businesses within the State’s strategic sectors. As a leader across these departments, she works to support high-quality job creation, catalyze private investment and build a diverse innovation ecosystem in New Jersey. Most recently, Ms. Coviello served as the NJEDA’s Executive Vice President for Technology, Life Sciences & Entrepreneurship, where she was responsible for working closely with the State’s emerging technology and life sciences companies and investors. Amadou Diarra, Ph.D. Senior Vice President, Global Policy, Advocacy & Government Affairs Bristol Myers Squibb & Chair, BioNJ Dr. Diarra leads an integrated organization focused on external environment dynamics, working with key stakeholders, including a Patient support organizations, healthcare professionals, policymakers and industry associations. He is passionate about partnering for improved health outcomes. Dr. Diarra joined Bristol Myers Squibb in 1991 as market research and business development manager, Africa Division. From 1999 to 2002, he led the company’s landmark philanthropic program, Secure the Future, a public-private partnership focused on care and support for women and children infected or affected by HIV/AIDS in Sub-Saharan Africa. In 2002, Dr. Diarra was appointed General Manager, Indonesia and in 2005 became General Manager, Turkey.
6 Mahako Etta, Ph.D., MPA Program Manager New Jersey Commission on Science, Innovation and Technology (CSIT) Dr. Etta has 15 years of work experience in higher education research, administration and workforce development. She is a Program Manager within the New Jersey Commission on Science, Innovation, and Technology (CSIT). In this role, Dr. Etta supports the planning and implementation of CSIT’s research and development grant products that help early stage New Jersey-based companies grow their technology from ideation to commercialization. Specifically, she oversees the allocation of approximately $4 million in grants annually. Dr. Etta also works closely with federal and State agencies to connect early stage companies with access to federal funds and business development resources. Andrew M. Evens, DO, MBA, MSc Assoc. Vice Chancellor, Clinical Innovation & Data Analytics, Rutgers Biomedical & Health Sciences; Assoc. Director (Clinical Services), Rutgers Cancer Institute of New Jersey; System Director, Medical Oncology & Oncology Lead, RWJBarnabasRutgers Medical Group, RWJBarnabas Health & Professor, Medicine, Rutgers Robert Wood Johnson Medical School Dr. Evens works to further the mission of the State’s only NCI-designated Comprehensive Cancer Center, helping to deliver innovative, high-quality, integrated cancer care across 15 acute care hospitals and associated oncology practices throughout the State of New Jersey. He works closely with RWJBH system leadership toward optimizing operational efficiency and effectiveness, physician recruitment, financial planning and program strategy. For Rutgers Biomedical and Health Sciences, he helps advance evidencebased practices to ensure dynamic and robust clinical decision support. Dr. Evens is also an international clinical expert in lymphoid malignancies, with research interests, including novel targeted therapeutic agents, predictive modeling and precision medicine. Aaron R. Fichtner, Ph.D., MCRP President New Jersey Council of County Colleges Dr. Fichtner is the President of the New Jersey Council of County Colleges, a non-profit organization, enshrined in state law, that supports and strengthens the State’s 18 community colleges. Dr. Fichtner served as Commissioner of the New Jersey Department of Labor and Workforce Development from September 2016 to January 2018. He joined the Department in 2010, serving as Assistant Commissioner for Labor Planning and Analysis and Deputy Commissioner. Before joining State government, Dr. Fichtner was the Director of Research and Evaluation at the Heldrich Center for Workforce Development at Rutgers University. Chris Gartin Managing Director, Healthcare Investment Banking J.P. Morgan As a client executive and key coverage partner, Mr. Gartin is responsible for relationships with many of our clients in the biotechnology industry. He joined J.P. Morgan in 2021, having previously spent 12 years in Citi’s Global Healthcare Investment Banking Group covering biotechnology companies. Mr. Gartin started his investment banking career in Lehman Brothers’ Global Healthcare Investment Banking Group. He received a Bachelor of Science in Business Administration from Georgetown University’s Robert McDonough School of Business. Sal Giovine, MBA Chief Financial Officer, Pharmaceutical BD & External Innovation Johnson & Johnson Mr. Giovine and his team provide financial leadership across Licensing, M&A, Corporate Venture and R&D collaboration transactions. Prior to his current role, Mr. Giovine was CFO of Xilio Therapeutics, Inc., an immuno-oncology company, where he led finance and certain of the company’s operating functions. Prior to Xilio, in his 15 year-tenure at Johnson & Johnson, Mr. Giovine held roles of increasing responsibility in corporate roles as well as across Johnson & Johnson’s Pharmaceutical and Consumer Health businesses. He began his career in the Private Equity practice of Deloitte LLP and hold a B.S. and M.B.A. from Fordham University in New York. SPEAKERS
7 Debbie Hart, MS, APR President & CEO BioNJ Ms. Hart worked alongside New Jersey’s biopharmaceutical industry leaders to establish BioNJ in 1994. Dedicated to BioNJ’s mission to help our Members help Patients, Ms. Hart is recognized as a respected thought leader and influential advocate. Under Ms. Hart’s leadership, BioNJ has become the trusted voice of the life sciences industry in New Jersey – working directly with legislative leaders in both Trenton and Washington D.C. to advance the life sciences industry, foster medical innovation and Patient access, while ensuring health equity and healthcare affordability. Most recently, she was named by Governor Murphy as the Chair of the New Jersey Commission on Science, Innovation and Technology. Eric Heil, MBA Managing Partner Medical Excellence Capital Mr. Heil is a venture capital investor and former CEO/serial entrepreneur with significant experience across the healthcare industry. In early 2021, he joined Medical Excellence Capital, LLC (MEC) as Managing Partner. MEC is an early stage life sciences venture fund that derives unique benefits from its proprietary network of leading physicians and academic medical centers. Mr. Heil currently serves on the boards of Nobias Therapeutics, Rejuvitas, Inc. and is the co-founder and board chair of ProJenX, a clinical-stage biotechnology company developing novel, brain-penetrant, targeted therapies to address debilitating brain diseases, with an initial focus on ALS. Prior to launching MEC, Mr. Heil was a co-founder and CEO of two venture-backed companies. Paul Howard, Ph.D. Senior Director, Public Policy Amicus Therapeutics Dr. Howard is responsible for ensuring consistent and appropriate implementation of overarching public policy initiatives and messages within the U.S. that help shape the legislative, reimbursement and regulatory environment for the development and marketing of products for the treatment of rare and genomic disorders. Previously, he was Senior Advisor to the Commissioner of the U.S. Food and Drug Administration (2017-19) on regulatory policy, strategic innovation initiatives and promoting competition to efficiently advance public health and safety. Prior to joining the U.S. FDA, Dr. Howard was a Senior Fellow and Director of Health Policy at the Manhattan Institute. He is currently a Co-Chair of the Regulatory Working Group and member of the Executive Committee at the Alliance for Artificial Intelligence in Healthcare; from 2020-22 he was also Co-Chair of the Regulatory Working Group the EveryLife Foundation. Pavita Howe Vice President, Innovation & Entrepreneurship BioNJ Ms. Howe is an entrepreneurial leader with experience in business development, marketing, strategy, program management, new products, launches, business planning, and building ecosystems at start-ups, academic institutions and large organizations. Most recently, she served as Director of Entrepreneurship Partnerships at Rutgers University, where she worked with internal and external partners to grow Rutgers’ entrepreneurial ecosystem, bring visibility to Rutgers affiliated start-ups, and connect them to valuable resources at the university and across the broader New Jersey entrepreneurial network. SPEAKERS Nitin Khanna CEO Archer Insights Mr. Khanna is the CEO and Founder of Archer Insights, an esteemed consulting firm that specializes in the life sciences industry. His innovative approach to creating the life sciences “Stairway to Commercialization” process has assisted numerous early stage life sciences companies in scaling their businesses while managing their cash flow and reducing waste. Under Mr. Khanna ‘s leadership, Archer Insights has demonstrated remarkable growth, achieving a consistent 40% year-over-year growth rate for the past five years. Mr. Khanna’s unwavering dedication to focusing on life sciences and his ability to build long-term partnerships with the office of the pharma CFOs has played a crucial role in the company’s success.
8 Rik Mehta, Pharm.D., JD, LL.M CEO Lactiga Dr. Mehta is an entrepreneur, health law expert, pharmacist, attorney, adjunct law professor and co-founder of Lactiga, an early stage biotech company in New Jersey. Dr. Mehta’s past experiences include senior positions at the US FDA and the DC Department of Health. His private sector experience includes executive roles overseeing drug approvals for rare diseases. Politically, Dr. Mehta made history in 2020 running for U.S. Senate and becoming the first Asian-American to win a statewide nomination in New Jersey. Dr. Mehta holds a bachelor’s in pharmacy from Rutgers, Pharm.D. from University of Arkansas, JD from Rutgers Law and LL.M in Global Health Law from Georgetown Law. Kara Moore, MIS Senior Advisor, Sector Development New Jersey Economic Development Authority Ms. Moore is the Sector Lead for Life Sciences at the New Jersey Economic Development Authority. She is focused on working with organizations across the State in this sector on growing and innovating in the state of New Jersey. Prior to the NJEDA, she led efforts connecting corporate partners to researchers at Rutgers University and Northwestern University. Ms. Moore holds a Master of Information Science from Indiana University. Kristine O’Keefe, CFA, CFP Executive Director JPMorgan Private Bank As a banker, Ms. O’Keefe works closely with her clients and their advisors to develop and execute wealth management strategies in areas of investment management, credit, banking, philanthropy and estate planning. Ms. O’Keefe joined J.P. Morgan in 2004 as an analyst in the Investment Bank. She joined the Private Bank in 2005, and since then has worked with many different types of clients and families on their wealth management goals. Ms. O’Keefe is passionate about helping families identify their priorities and then delivering the right resources at J.P. Morgan to meet their needs. Ms. O’Keefe received her MBA from the Kellogg School of Management and graduated with a BA in Economics and English from Dartmouth College. SPEAKERS Ivor Macleod Chief Financial Officer SCYNEXIS Mr. Macleod joins SCYNEXIS from Athersys, Inc. where he had served as Chief Financial Officer since January of 2020. Previously he served as the Chief Financial Officer and Chief Compliance Officer of Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., a Japanese research-based human healthcare company that discovers, develops and markets products globally, from 2015 to 2018. Prior to joining Eisai, Mr. Macleod served as Vice President of Finance for Merck Research Labs at Merck & Co., Inc., a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, from 2012 to 2015. Alan Leeds, JD Partner, Life Sciences Transactions Practice Leader Morgan Lewis Leader of the firm’s life sciences transactions practice and a co-leader of the firm’s global life sciences industry team, Mr. Leeds represents life sciences companies from early stage biotechnology start-ups to global pharmaceutical companies, as well as specialty pharma, medical device and other technology companies. He also works with venture capital firms that focus on the life sciences industry. Mr. Leed’s practice includes negotiating and structuring strategic alliances and other complex collaborations, corporate partnering arrangements, licensing transactions, acquisitions and divestitures, manufacturing and supply agreements, distribution arrangements, co-promotion arrangements and joint ventures. He assists clients with the full spectrum of commercial activities, from early stage research collaborations to global strategic alliances for the development and commercialization of products.
9 Mike Poisel, M.S., MBA Executive Director Penn Center for Innovation (PCI Ventures) Since joining the University of Pennsylvania in 2009, Mr. Poisel has been building entrepreneurial programs for the university. He currently manages PCI Ventures, which includes UPstart, UPadvisors and Venture WarmUP, while also providing incubation services at Penn’s incubator, The Pennovation Center. As part of these programs, Mr. Poisel has participated in the founding of over 250 companies, which have gone on to raise over $500 million in funding. Prior to Penn, Mr. Poisel made investments in enterprise software and business services for NewSpring Capital, Apax Partners and GE Capital spanning more than ten years in private equity. He began his career in manufacturing operations for General Electric/Lockheed Martin. Ravi Raghunathan, CPA Partner CohnReznick Mr. Raghunathan serves as the firm’s Life Sciences Industry Leader. The clients served by the Life Sciences Industry Practice include middle-market companies ranging from early stage and emerging growth companies to venture- and private equity-backed companies and later-stage publicly traded companies. Mr. Raghunathan has been involved in a number of due diligence projects, internal control assessments, going public and private transactions, secondary offerings and other SEC filings. Mr. Raghunathan has more than 25 years of accounting experience and specializes in providing services to biotechnology and pharma, medical devices and healthcare IT. John Ritter, JD, MBA Director, Office of Technology Licensing Princeton University In his role, Mr. Ritter manages portfolios, including negotiating agreements, for certain high level inventors/center directors; reviews and oversees negotiations of all option, license and other agreements to ensure appropriate financial and diligence terms; coordinates with university counsel and Conflict of Interest Committees the necessary agreements and policies associated with the formation and licensing of university technology to faculty-owned start-up companies; educates faculty, staff and students about intellectual property (IP), conflict of interest, technology transfer and entrepreneurial issues; interacts with outside patent attorneys on issues related to patents, patent applications; provides input to sponsored research agreements with intellectual property terms; and manages accelerator fund program to provide gap-funding to promising early stage technologies. Phil Ross, M.D., MBA Global Chair, Investment Banking J.P. Morgan As a client executive and key coverage partner, Dr. Ross is responsible for relationships with many of our clients in the biotechnology industry. He also leverages his biotechnology expertise for J.P. Morgan’s global pharmaceutical coverage effort. Dr. Ross joined Hambrecht & Quist’s Corporate Finance department in January 2000. Prior to joining Chase H&Q, he was an associate at CIBC World Markets. Dr. Ross is a diplomat to the American Board of Quality Assurance and Utilization Review Physicians and a Certified Public Accountant. He received a medical degree from the Philadelphia College of Osteopathic Medicine, an MBA from St. Joseph’s University and a BS in management from the A.B. Freeman School of Business at Tulane University. David Schwartz, JD Partner Morgan Lewis Mr. Schwartz is a Partner and leads the Corporate, Business and Transactional practice at Morgan Lewis Princeton. He advises a broad range of clients in the life sciences, healthcare and technology industries. Mr. Schwartz focuses on a variety of capital markets and corporate finance transactions, mergers and acquisitions and corporate governance matters. He works with clients of all sizes, including start-ups and emerging businesses, publicly held middle-market companies and venture capital firms and underwriters. Mr. Schwartz is ranked in Chambers USA for his capital markets and M&A experience. He regularly advises clients in connection with initial public offerings (IPOs), follow-on offerings, confidentially marketed public offerings, at-the-market offerings, private investments in public equity (PIPEs) and registered direct offerings, in addition to venture capital, private equity, mergers and acquisitions, going-private and other strategic transactions. SPEAKERS
10 Ofra Weinberger, Ph.D. Director, Licensing, Columbia Tech Ventures; Associate VP, Tech Transfer & Intellectual Property Columbia University, Columbia Tech Ventures (NY) Dr. Weinberger has extensive experience commercializing discoveries that were developed in university labs, negotiating licenses and research collaboration agreements with industry, developing strategic alliances and spinning out companies to commercialize university technologies. Leading the licensing and start-up formation team for Columbia Technology Ventures, she oversees the management of over 400 inventions, 200 patents, approximately 100 licenses to industry and the formation of approximately 20+ new start-ups per year, involving over 750 inventors across Columbia’s campuses, in a varied portfolio comprising both life sciences and physical sciences opportunities, across research fields such as biology, IT, clean tech, devices, big data, nanotechnology, materials science and more. Mike Wiley, JD, MBA Vice President Foundation Venture Capital Group Mr. Wiley is Vice President of the New Jersey Health Foundation and its affiliate, Foundation Venture Capital Group, LLC. These organizations provide funding and/or pre-seed investments for health-related projects and start-up companies founded by researchers at the following affiliated organizations: Cooper University Healthcare, Hackensack Meridian Health, Kessler Foundation, New Jersey Institute of Technology, Princeton University, Rowan University, Rutgers University and Stevens Institute of Technology. Mr. Wiley assists the Foundation Venture Capital Group’s health-related portfolio companies by providing funding and assisting with the various strategic, operational and back-office management issues associated with developing and growing early stage health-related companies. SPEAKERS Gina Tedesco, MBA Managing Director Golden Seeds Ms. Tedesco, an active investor, and serial entrepreneur is the Managing Member of Amala Ventures, Managing Director and NJ Chapter Lead of Golden Seeds and a member and board trustee of Jumpstart NJ Angel Network. Her career of 30 years includes co-founding three successful start-up ventures, overseeing postings in finance and M&A with a global pharmaceutical company and industry expertise in internet technology, software as a service technologies, biotech, pharmaceuticals and education. Fluent in English, French and Portuguese, Ms. Tedesco earned a B.S. in Mechanical Engineering from the University of Massachusetts at Amherst and an MBA in International Business with a concentration in Finance from The George Washington University. Kristy Shuda McGuire, M.S., Ph.D Biomedical Studies The Wistar Institute Dr. Shuda McGuire plays a vital role administering the educational programs at Wistar. Prior to joining Wistar, Dr. Shuda McGuire was Assistant Dean in the College of Science & Mathematics/School of Health Professions at Rowan University, where she handled all academic issues for approximately 6,000 undergraduate and graduate students (33% of total University enrollment) and coordinated enrollment for nine departments. Previously, Dr. Shuda McGuire was an associate professor in the biology department at Community College of Philadelphia, and from 2013-2018, served as the academic coordinator for the Biomedical Technician Training (BTT) Program, a partnership between The Wistar Institute and Community College of Philadelphia that prepares community college students for career opportunities as research technicians to reinforce the region’s life sciences workforce.
11 EXHIBIT HALL www.cohnreznick.com www.dlapiper.com www.jpmorgan.com/global www.marcumllp.com www.middlesexcountynj.gov www.njeda.com www.princetonbiolabs.com www.rsmus.com www.scisafe.com www.tcggreenchem.com www.thermofisher.com www.withum.com www.wipshh.com www.augustetech.com www.breakthroughmedicines.com www.centriconsulting.com www.cfgi.com www.circularedge.com
12 INSTITUTION ALLEY Columbia University Columbia Technology Ventures is the technology transfer office for Columbia University and a central location for many of the technology development initiatives, entrepreneurial activities, external industry collaborations and commercially-oriented multidisciplinary technology innovations across the university. CTV’s core mission is to facilitate the transfer of inventions from academic research labs to the market for the benefit of society on a local, national and global basis. Each year, CTV manages more than 400 invention disclosures, 100 license deals and 20 new IP-backed start-ups, involving over 750 inventors across Columbia’s campuses. CTV currently has over 1,200 patent assets available for licensing, across research fields such as bio, IT, clean tech, devices, big data, nanotechnology, materials science and more. Contact: Mitchell Fullerton Alliance Manager mf3399@adcu.columbia.edu New Jersey Innovation Institute With more than 125 undergraduate and graduate degree programs in six specialized schools, NJIT is a leading public polytechnic university. In addition to its R1 Carnegie Classification, the university saw its largest and most diverse entering class in school history at 1,600 enrollees in 2022. The State’s largest high growth start-up incubator, VentureLink@NJIT, provides space, mentorship and resources. With 55 established businesses, office and lab space, it offers coaching, workshops and community. New Jersey Innovation Institute serves as a conduit from student and faculty-led ideas to New Jersey’s broader technology community. Contact: Kathy Naasz Vice President, Strategic Partnerships & Entrepreneurship Kathy.Naasz@njii.com New York University Technology Opportunities & Ventures (TOV) is the technology commercialization unit of NYU, serving all of the University’s campuses, colleges and schools. TOV’s mission is to translate the outputs of the University’s $1.1 billion research base into commercial solutions and technologies to maximize their social and economic impact. NYU has a strong track record of new venture creations and successfully commercializing promising discoveries. More than 50 products have come to market, based on NYU innovations. Over 200 new companies have been created based on NYU intellectual property. TOV also helps to facilitate research collaborations between NYU researchers and industry. Contact: Abram Goldfinger Executive Director, Office of Industrial Liaison Abram.Goldfinger@nyulangone.org Princeton University Princeton University is a vibrant community of scholarship and learning that stands in the nation’s service and the service of humanity. Its educational mission is to prepare students to pursue meaningful lives and to help address the challenges of the future. The scope of research carried out by Princeton researchers ranges from robust engagement with the major challenges of our time – energy, the environment, health, security – to probing the origin of the universe. Our researchers expand the confines of the known and strive to find solutions to societal challenges through creative, systematic and fact-based inquiry. Contact: Cortney Cavanaugh New Ventures and Licensing Associate ccavanaugh@princeton.edu
13 INSTITUTION ALLEY Rowan University A top 100 national public research institution, Rowan University offers bachelor’s through doctoral and professional programs in person and online to 22,000 students. With eight colleges and nine schools, Rowan focuses on practical research at the intersection of engineering, medicine, science and business while ensuring excellence in undergraduate education. It has earned national recognition for innovation, high-quality, affordable education and public-private partnerships. One of two public universities in the nation to offer M.D. and D.O. degree programs, Rowan is also developing New Jersey’s first veterinary medical school. Contact: Tabbetha Dobbins Executive Director, Office of Industrial Liaison dobbins@rowan.edu Rutgers University Rutgers, The State University of New Jersey, is a leading national research university and the state of New Jersey’s preeminent, comprehensive public institution of higher education. Established in 1766, the University is the eighth oldest higher education institution in the United States. More than 70,000 students and 23,600 full- and part-time faculty and staff learn, work and serve the public at Rutgers locations across New Jersey and around the world. www.rutgers.edu As the premier public research university in the State, Rutgers is dedicated to teaching that meets the highest standards of excellence, to conducting cutting-edge research that breaks new ground and aids the State’s economy, businesses, and industries, and to providing services, solutions and clinical care that help individuals and the local, national and global communities where they live. research.rutgers.edu Contact: Dan Benderly Associate Director, New Ventures, Innovation Ventures dan.benderly@rutgers.edu University of Pennsylvania The Penn Center for Innovation (PCI) helps to translate discoveries and ideas created at the University of Pennsylvania into new products and businesses for societal benefit. PCI actively facilitates a broad range of technology development connections between Penn and the private sector. Whether the end result is a technology license, an R&D alliance or the formation of a new venture, PCI serves as a dedicated one-stop shop for commercial partnering with Penn. Contact: Laurie Actman Chief Marketing, Communications & Program Officer lactman@upenn.edu
14 POSTER PRESENTER Novelstar Pharmaceuticals Novelstar Pharmaceuticals was founded in August 2018 with a focus on the development of novel drug delivery systems (505(b)(2) NDA), high-quality complex or niche generic products (ANDA), and providing the best service to the pharmaceutical industry. We have built a GMP facility, including manufacturing and analytical labs (14,000 sq ft in Cranbury, NJ) and an efficient R&D team. Our expertise covers different drug delivery systems and technologies, including modified-release oral solids, liquids, semisolids, injectables and nanoparticle platforms. We have the capability to work as a CDMO to develop oral solids from R&D to exhibit batches for filing and clinical trial materials for other dosage forms. Contact: Shao Fu Vice President of Operations sfu@nvspharm.com The New Jersey Equity in Commercialization Collective (NJECC) is an NSF ADVANCE partnership program that was created to address the significant equity issues in academic technology commercialization and eliminate systemic barriers at all levels. The aim of the program is to increase the diversity of STEM faculty researchers who participate in New Jersey’s entrepreneurship and innovation ecosystem. NJECC partners with universities and organizations throughout the region as part of this systemic change initiative. The NJECC team is comprised of professionals with diverse backgrounds in research and development, technology commercialization and entrepreneurship, who hold strong commitments to fostering diversity and inclusion. A special thank you to NJECC for supporting entrepreneurs attending BioNJ’s BioPartnering Conference Actinobac Biomed, Inc. Actinobac Biomed, Inc. is a biopharmaceutical company based on technology discovered by Dr. Scott Kachlany in his academic laboratory at Rutgers School of Dental Medicine. Leukothera, a bacterial protein usually found in the human mouth, is a first-in-class novel biologic to treat patients with hematological malignancies and autoimmune diseases. Leukothera is unique in that it selectively and rapidly kills leukocytes expressing activated LFA-1, while leaving the healthy immune system intact. This results in an excellent benefit to risk ratio. The FDA has approved Actinobac’s IND application to evaluate Leukothera in Patients with relapsed and refractory hematological malignancies. Contact: Scott Kachlany, Ph.D. Founder & Chief Scientist scottkachlany@actinobac.com EMERGING COMPANY PRESENTER PROFILES
15 EMERGING COMPANY PRESENTER PROFILES AGelity Biomechanics Corporation AGelity Biomechanics Corp. (“AGelity”) is a private orthopedic device company that is developing innovative cartilage repair products that look, feel and act like native cartilage. AGelity is the first spin-out of the Hospital for Special Surgery, the premier orthopedic hospital in the world. Our aim is to provide sports medicine surgeons with easy, safe and effective total cartilage repair products in specific anatomical areas. Our initial focus is on osteochondral defects of the knee, to be followed by applications in foot and ankle, shoulder, hip and hand. Contact: Dennis O’Dowd CEO odowd@agelitybiomechanics.com AMPEL BioSolutions AMPEL BioSolutions is a precision medicine company commercializing a development pipeline of CLIA-certified gene expression tests for blood or tissue samples that provide clinical decision support by determining disease status, identifying molecular pathway and predicting drug options. AMPEL’s technology is a cloud-based platform that hosts proprietary DNA/RNA analytic tools and machine learning algorithms covered by 25+ filed/pending patents and 90+ peer-reviewed publications. AMPEL’s platform technology covers over 95% of all known genes and AMPEL’s exclusive curated database of >15,000 individual gene expression profiles with rich clinical information fuels machine learning predictions based on evidence. Our focus is autoimmunity. Contact: Amrie Grammer Founder, President & Chief Scientific Officer Aspargo Laboratories, Inc. Aspargo Laboratories, Inc., located in Englewood Cliffs, New Jersey, is a commercial stage, specialty pharmaceutical company. Aspargo’s current focus is to commercialize an oral spray formulation of sildenafil citrate, the active ingredient in Viagra®. Aspargo is the U.S. and international licensee of the patent rights covering Sildenafil Oral Spray from Farmalider, S.A. of Madrid, Spain (www.farmalider.com). For additional information, please visit our website at https://aspargolabs.com/. Contact: Michael Demurjian CEO MDemurjian@aspargolabs.com Avistone Biotechnology Founded in 2010, Avistone Biotechnology is a private, global Oncology company, focused on targeted therapeutics for lung cancer. The company has a differentiated pipeline, in-house R&D capabilities, an emerging commercial presence in China and a highly experienced management team/Board of Directors. The company’s pipeline comprises of five assets, including PLB1001 (cMETi), PLB1004 (EGFRi) and ANS01 (cMETi) across various stages of development (Registered/Near Commercial to preclinical). The company employees 65 employees globally with headquarters in Beijing, China. The company completed a strategic financing (Series A) of $200M in December 2021 from Vivo Capital, Bain Capital and Primavera Capital. Contact: David Chung, MHS, MBA Chief Business Officer david.chung@avistonebio.onmicrosoft.com
16 EMERGING COMPANY PRESENTER PROFILES Biosortia Microbiomics A traction-proven drug discovery platform for delivering clinically preoptimized small molecules from microbiomes. The problem Biosortia solves is the lack of clinical success of treatments and cures due to an inability to obtain the best molecules and data to start a drug discovery program. Biosortia solves the problem with a new breakthrough technology with unprecedented access to unculturable microbes’ natural chemistry at seven orders of magnitude beyond current technologies. The opportunity of microbiome-based small molecule availability will be magnitudes over current availability allowing screening, data, optimization of machine learning and artificial intelligence platforms. Raising seed/bridge for revenue. Contact: Ross Youngs Founder & CEO ryoungs@biosortia.com Canget BioTekpharma Canget is developing a new class of drugs that eliminates cancer and addresses multiple mechanisms of drug resistance. By acting as a ‘molecular glue degrader’, our lead candidate FL118 directly binds to and degrades the multifunctional master regulator DDX5 through the proteasome degradation pathway without decreasing DDX5 mRNA. FL118 indirectly controls DDX5 downstream targets (c-Myc, survivin, mutant Kras) to inhibit cancer initiation, development, metastasis, recurrence and treatment resistance. FL118 is a small molecule, not a cytotoxic drug, that has a favorable safety profile as demonstrated in multiple animal models. We have strong IP protection with multiple issued and pending patents. Contact: John Seman, M.S. CEO johnjseman@gmail.com Couragene, Inc. Couragene’s vision is to develop life transforming cures by delivering genetic therapeutics to targets once undruggable. Genetic medicines have the potential to cure a wide range of human diseases. Yet, the broad application of genetic medicines remains limited by the delivery challenges. Couragene leverages its breakthrough delivery platforms to develop non-viral genome modification therapies for genetic disorders. Couragene’s STEP (Stimuli-responsive Traceless Engineering Platform) technology has demonstrated great potential to overcome the delivery hurdles for treatment of various diseases, including neurogenetic disorders. Contact: Amy Liao, Ph.D., M.S. CEO amy.liao@couragene.com Curio Digital Therapeutics, Inc. Curio is pioneering digital therapeutic solutions and interventions across the health continuum throughout the cycle of life of women. Curio offers a low-code/no-code multi-modal platform combining AR, digital behavioral therapy, care-escalation and health coach integration to address unmet needs. Empowering women with multi-model digital health solutions for every phase of their life. Contact: Shailja Dixit, M.D., M.S., MPH/MBA CEO shailja.dixit@gmail.com
17 EMERGING COMPANY PRESENTER PROFILES De Laboratory, Rutgers Cancer Institute of New Jersey De Laboratory at Rutgers Cancer Institute develops genomics technologies and applications for cancer diagnostics and precision medicine. The group, led by Dr. Subhajyoti De, Associate Professor with over 12 years of professional experience, performs fundamental research with NIH funding that translates to technology development for advancing precision medicine in cancer. A translational research focus has been to develop non-invasive, low cost, blood-based cancer diagnostics platform for tracking cancer progression. Contact: Subhajyoti De, Ph.D. Associate Professor subhajyoti.de@rutgers.edu EmphyCorp Pharmaceutical EmphyCorp is a private New Jersey biotech that specializes in Rx Non-Steroidal Nasal Sprays with no adverse effects that has completed a Phase III Clinical Trial for treating Pulmonary Fibrosis/IPF, Long COVID and COVID-19. EmphyCorp has (8) U.S. Drug Patents/70+ worldwide including 3 new ones – (Hypoxemia/Dyspnea/Coughing, Apoptosis of Myofibroblasts and Coronavirus/ Influenza). Successfully completed (8) Animal Studies and (23) sets of U.S. Clinicals for Pulmonary Fibrosis, Long COVID, COVID-19, Cystic Fibrosis, Asthma, COPD, Allergic Rhinitis, Congestion, Flu, along with treating 3 million Real World Use Patients in Chinese Hospitals with a Chinese Approved, Nasal Spray Formulation. Four peer reviews published. Contact: Robert Millar, MBA President Bob.Millar.HQ@emphycorp.com Evrys Bio Evrys Bio develops broad spectrum anti-viral compounds that target host cell molecular targets. Focuses are respiratory diseases, hepatitis, opportunistic transplantation infections and pandemic preparedness. Because Evrys Bio products address the infectious disease condition, as opposed to targeting a specific virus-type, the practice of medicine will be transformed. Imagine being prescribed a safe, broad-spectrum antiviral based on your symptom’s presentation, and perhaps, without the need for diagnostic confirmation of infecting virus. These highly innovative products have begun clinical manufacturing, and thus we are making great progress in solving real clinical challenges and unmet medical need. Contact: Lillian Chiang, Ph.D., MBA CEO, Founder, President lillian@evrysbio.com Feldan Therapeutics Feldan Therapeutics is a preclinical biotechnology company developing leading-edge treatments based on its proprietary peptidebased intracellular delivery technology, the Feldan Shuttle platform. It is a safe, rapid and efficient delivery method that unlocks the potential of targeting intracellular components, a breakthrough which will in turn lead to a generation of novel classes of drugs. Feldan’s current focus is to bring its first drug to clinical trial; its first-in-human program is called FLD-103 and is a treatment for nodular Basal Cell Carcinoma. In parallel, Feldan is also working on pulmonary projects to expand its therapeutic pipeline. Contact: Francois-Thomas Michaud, Ph.D., Eng. Co-Founder & CEO ftmichaud@feldan.com
18 EMERGING COMPANY PRESENTER PROFILES First Ascent Biomedical First Ascent Biomedical’s platform helps Patients today by providing individualized cancer treatment plans, accelerating new drugs into the clinic for Patients tomorrow and reshaping cancer treatment for the Patients of the future. Our technology allows us to rapidly grow cancer stem cells and tumor bulk from a Patient’s biopsy. We test 100s of FDA-approved drugs against cells to measure response. Our AI engine examines every weakness, not just a few DNA-based markers, but every weakness, and the doctor receives a report in a week. We’re the only platform designed to help Patients while advancing pharmaceutical drug discovery simultaneously. Contact: Jim Foote, MBA CEO & Co-Founder jfoote@firstascentbio.com Haima Therapeutics Haima Therapeutics is a pre-clinical stage biopharma company developing cell-inspired therapies for the treatment of bleeding and a variety of blood-related diseases. Haima’s initial focus is on platelet inspired therapies to mitigate active bleeding and bleeding risks after traumatic injury, surgery and thrombocytopenia. Haima’s lead technology is called SynthoPlate, a novel, fully synthetic hemostatic agent that mitigates bleeding by acting at the site of injury and amplifying your body’s natural clotting mechanisms. Haima is currently raising Series A funds. Contact: Michael Bruckman, Ph.D. CEO mbruckman@haimatherapeutics.com Hillstream Biopharma, Inc. Hillstream BioPharma, Inc. is a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging anti-cancer mechanism resulting in iron mediated cell death, and immuno-oncology targeted novel biologics. The most advanced candidate, HSB-1216, expected to enter clinical trials in 2023, targets ferroptosis, an emerging anticancer mechanism resulting in iron mediated cell death (IMCD) of drug resistant cancers. The company’s emerging immuno-oncology pipeline is led by the HSB-1940 Quatrabody™, an anti-PD-1 novel biologic coated onto Quatramers expected to enter the clinic in 2024. Hillstream’s Quatramer™ proprietary tumor targeting platform extends duration of action and minimizes off-target toxicity. Contact: Randy Milby, MBA CEO rmilby@hillstreambio.com Invea Therapeutics Invea Therapeutics is a biotechnology company using AI and machine-learning to identify precision therapeutics for chronic inflammatory disorders. Our primary focus is unraveling the gut-brain axis to pinpoint the underlying mechanisms that drive dysregulation and lead to chronic inflammation and its progression across gastrointestinal (GI) and non-GI disorders. Our differentiated approach expedites and de-risks the discovery and development of innovative programs while optimizing capital efficiency and increasing the likelihood of clinical and regulatory success. Our pipeline of three precision medicine programs is primed to transform the long-term treatment of Patients who have resistance to, partial response to, or no therapeutic options. Contact: Aman Kant Chief Business Officer akant@inveatx.com
19 EMERGING COMPANY PRESENTER PROFILES JOGO Health JOGO uses wearable sensors and an AI driven mobile app to provide virtual treatments for neuromuscular dysfunctions in chronic stroke, pelvic floor disorders, chronic pain and tremors by tapping into the natural neuroplasticity of the central nervous system (CNS). JOGO treatments are delivered via JOGO’s own virtual clinic and through a network of partner providers. JOGO is FDA 510K exempted and reimbursed by Medicare and most commercial payers. Mayo Clinic is a strategic partner and an investor, developing early detection and treatments for essential, functional and Parkinsonian tremors. Co-founder’s previous AI venture was acquired by IQVIA. Contact: Siva Nadarajah Co-Founder & President siva@jogohealth.com Jubilant Therapeutics, Inc. Jubilant Therapeutics is a clinical-stage biopharmaceutical company developing precision oral medicines with enhanced therapeutic index to address unmet medical needs in oncology and autoimmune diseases for genetically defined Patients. Its advanced structurebased discovery engine, TIBEO (Therapeutic Index and Brain Exposure Optimization), has been validated through successful partnerships. The company’s pipeline consists of a first-in-class dual epigenetic modifier, JBI-802, currently in a Phase I/II clinical trial in multiple tumors, a novel brain-penetrant modulator of PRMT5 for which an IND has been accepted, brain-penetrant and gut restrictive PDL1 inhibitors, as well as PAD4 inhibitors for oncology and inflammatory indications. Contact: Shyam Pattabiraman, MBA Chief Financial Officer shyam.pattabiraman@jubilanttx.com Lactiga Lactiga is an award-winning, venture-backed biotherapeutics company committed to restoring mucosal immunity in Patients with rare immunodeficiency diseases. We are unlocking the full therapeutic value of IgA antibodies developed from human milk to create the next generation of anti-infectives to fight debilitating pathogens including SARS-CoV-2 and its variants. Lactiga holds three granted patents in support of its LCTG-001 program to prevent life-threatening, respiratory mucosal infections in Patients with immunodeficiencies like common variable immune deficiency (CVID) and its NIH-funded program LCTG-002 to develop an airway therapeutic to reduce hospitalizations and infections from COVID-19 and its variants in vulnerable populations. Contact: Viraj Mane, Ph.D. Chief Scientific Officer viraj@lactiga.com Likarda Likarda is a biotech company developing cell therapies and enabling technologies to transform the way cell therapies are delivered and function. Our patented platform, Core-Shell Spherification® (CSS™), is an entirely new modality for the formulation and delivery of cell therapies. Our platform is customizable, because each cell therapy is unique and there is no “one-size-fits-all” approach. Likarda is developing treatments for diabetes, osteoarthritis and joint pain. We’re in pre-clinical studies leveraging our cell therapy platform for the protection and delivery of cells in applications ranging from short-term to long-term treatments. Contact: Karthik Ramachandran, Ph.D. Co-Founder & Chief Operating Officer Karthik@likarda.com
20 EMERGING COMPANY PRESENTER PROFILES LinusBio LinusBio leads the field of precision exposome medicine. We have the first and only temporal exposomic sequencing platform for identifying novel biomarkers of complex health conditions, such as autism and ALS. Our proprietary technology bridges genomics and the environment by mapping the dynamic patterns of an individual’s unique biological response to environmental exposures over time at a molecular level. For our biopharma partners, our temporal exposomic biomarkers can identify novel biological pathways, serve as objective molecular endpoints in clinical trials, provide deep phenotyping and identify health conditions even before symptoms emerge. Contact: Manish Arora, Ph.D., MPH, BDS Co-Founder & CEO manish.arora@linusbio.com NAKI Therapeutics NAKI Therapeutics is an innovative research-focused biopharmaceutical company. Our core technology is surrounding Chimeric Antigen Receptor (CAR)-Natural Killer (NK) immunotherapy with ground-breaking allogeneic or “off-the-shelf” expansion technology and a firstin-class solid tumor molecular target-CD147. Our approach is to re-engineer NK cells-which belong to the human innate immune system to target the specific cancer cell surface marker CD147, and thereby kill the cancer cells more effectively and safely in comparison to existing treatments. Our initial indication is hepatocellular carcinoma (HCC), a devastating solid tumor with marginally effective standard of care. Contact: Guanghui Hu, Ph.D. CEO guanghuihu2@gmail.com Nanocan Therapeutics Corporation Based in Princeton, NJ, Nanocan Therapeutics holds the exclusive global license to patented technology developed at Harvard’s Dana Farber Cancer Institute. Nanocan has developed NEST™ (Nanoparticle Encapsulated Smart Technology), enabling immune-modulating agents to work more effectively by locating and releasing active therapeutics in the tumor micro-environment. Nanocan has received almost $3 million in NIH awards and maintains development partnerships with Dana Farber and Johns Hopkins. NEST™ will be available in three distinct formulations targeting seven solid cancer indications and will file its first IND to open Phase I trials in prostate cancer later this year. Contact: Eric Broyles, JD Founder & CEO ebroyles@nanocan.life Neumentum, Inc. Neumentum is a non-opioid analgesic specialty pharmaceutical company with four non-opioid products in development to treat pain. Neumentum has two lead product candidates being developed to address the opioid crisis. NTM-001, currently in Phase 3, is an IV formulation of Toradol (ketorolac) with Phase I results showing it may provide consistent, steady blood plasma levels of ketorolac over 24 hours and a durable analgesic effect. NTM-006, a Phase 2 novel oral analgesic with a target indication for acute and chronic pain that has demonstrated meaningful analgesia in a Phase 2a Proof of Concept study, was licensed from Johnson & Johnson. Contact: Taggart McGurrin, CPA, MBA, JD President & Chief Business Officer taggartmcgurrin@neumentum.com
21 EMERGING COMPANY PRESENTER PROFILES Neurxstem, Inc. Neurxstem is an avant-garde Predictive and Precision Genomic Medicine Company. It has made a novel, first in class, patented Neural Organoid Platform™ that delivers the world’s first in class and most advanced synthetic mimic of the human central nervous system ‘(CNS)-in-a-dish’. Neural Organoid Platform™ utility includes diagnose brain disorders and diseases early, discover novel therapeutic targets, perform drug toxicity, safety, and efficacy testing in human models and pre-stratify Patient subtypes and likely therapeutic responsiveness for clinical trials. Additional utility patents were filed from 2018 onwards to secure additional intellectual property rights for Alzheimer’s, Parkinson’s, autism and their comorbidities, as well as aging, brain cancer, pain and opioid addiction. Contact: Rene Anand, Ph.D., M.S. Founder & CEO rene.anand@neurxstem.com Osmol Therapeutics, Inc. Osmol is a spin-out of Yale University developing a novel treatment, OSM-0205, to prevent chemotherapy induced peripheral neuropathy (CIPN) caused by microtubule-based chemotherapy agents, including taxanes, the leading breast cancer chemotherapy treatment. With no approved treatments, Patients’ only option to prevent CIPN is to reduce the dose or length of chemotherapy treatment, potentially effecting outcomes. The company’s initial focus is breast cancer Patients where up to 80% of Patients treated with taxanes develop CIPN. Osmol has completed IND enabling studies to file an IND in Q2, 2023 to commence a Phase 1 clinical study in Q3 2023. Contact: Bob Linke, MBA President & CEO rlinke@osmoltherapeutics.com OsseoPrint 3D, LLC Started by Dr. Greyf, a robotic dental implantologist with 20+ years of bone grafting experience, OsseoPrint 3D is developing an integrated system that consists of a proprietary aseptic 3D printer and AI-driven software. OsseoPrint’s system can be placed into the surgical suite and creates in less than one hour an immediately implantable, Patient-specific bone scaffold for bone regeneration surgery. Use of the Patient-specific scaffold will significantly reduce surgical complications, surgical time and the cost of the surgery. OsseoPrint’s system addresses a market of about $50 billion and will improve surgical outcomes for medical, dental and veterinary procedures. Contact: Arthur Greyf Chief Operating Officer agreyf@osseoprint3d.com Panavance Therapeutics Panavance Therapeutics is a privately held, clinical-stage pharmaceutical company. Panavance’s lead program, GP-2250, is a tumor cell selective and broadly active agent designed to disrupt energy metabolism, resulting in cancer cell death. GP-2250 is currently in Phase 1 in cancer Patients and is advancing towards a Phase 3 clinical trial, as a first-line maintenance therapy for pancreatic cancer in a population for which there are no FDA approved agents. Additionally, GP-2250 is being developed for the treatment of ovarian cancer based on promising preclinical data. The pivotal pancreatic and ovarian cancer studies are expected to start in early 2024. Contact: Greg Bosch, MBA CEO Greg.Bosch@panavance.com
22 EMERGING COMPANY PRESENTER PROFILES PRAMOMOLECULAR GmbH siRNAs can theoretically downregulate any disease-causing protein: no disease-causing protein – no disease! But siRNAs are large, instable and electrically charged. Therefore, they cannot reach their target cells. So far, there are only efficient, well-tolerated delivery systems for the liver. PRAMOMOLECULAR offers delivery in vivo into the cells of the lung, heart and pancreas, developing drug candidates against lung cancer, pancreatic cancer and heart failure. Our transport molecules have a particularly simple structure and do not require the interference-prone, immunostimulatory formulation of nanoparticles. The whole drug candidate can be synthesized GMP compliant by standard technology. “Pramo” means “ferry” in Esperanto. Contact: Merle Fuchs, Ph.D. Co-Founder & CEO fuchs@technologiecontor.de PsychoGenics Drug Discovery PsychoGenics is using its novel SmartCube® platform to develop new treatments for psychiatric and neurological disorders. The company has industrialized phenotypic screening in mice using its SmartCube® screening platform designed for rapid behavioral evaluation of compounds. This proprietary platform uses artificial intelligence, comparing the mouse behavior to a database of reference compounds to provide a rapid prediction of the therapeutic use of the compound. Combined with a highly experienced team of drug hunters, projects can move from drug hit to development candidate in a target-agnostic manner much more efficiently than conventional target-based discovery. Contact: Mark Varney, Ph.D. Chief Scientific Officer mark.varney@psychogenics.com RAPT Ventures, Inc. (RVI) RAPT Ventures was founded to bring the power of neuroscience into the home, giving individuals the ability to enhance brain performance for themselves and the people they love. Our trailblazing research and ingenuity leverage the power of brain plasticity to develop, support and maintain a healthy brain from the outside in. Our products deliver tailored auditory experiences to create specific neuronal responses that support brain structure and the processes that determine cognitive performance throughout life. Their benefits range from creating a better physiological foundation for language processing in infants to strengthening deteriorating neural systems in older adults. Contact: Julia Whitehead, MBA Co-Founder jwhitehead@raptventures.com Reset Pharmaceuticals, Inc. Reset Pharma is a neuro-biotechnology company dedicated to transforming brain health. We’re bringing science to psilocybin to help people rise above the trauma of a life-threatening medical illness. Reset Pharma acquired an exclusive worldwide license from NYU Langone Health for intellectual property associated with the use of psilocybin for the treatment of mental illness in Patients with life-threatening diseases. The company’s focus lies where needs are most urgent: Demoralization Syndrome in Patients with cancer. While Demoralization Syndrome is often mis-diagnosed as MDD, current treatments, including antidepressants, are ineffective in these Patients. Reset Pharma is developing novel, proprietary formulations of psylocibin-related products to treat these underserved Patients. Contact: Innes Meldrum President & CEO imeldrum@resetpharma.com
23 EMERGING COMPANY PRESENTER PROFILES Respond Health Respond Health enables clinical discovery that can reach, engage and retain Patients all along their journey in real-time. The AI-enabled RESPOND platform provides a configurable hub-and-spoke solution that is easy to deploy from study to study. RESPONDS’s decentralized event-driven technology, advanced analytics and workflows, brings infrastructure and design to out-Patient practices and community programs. Its engagement-based responsive architecture provides a personalized user experience for Patients that rewards their contributions leading to higher retention. RESPOND delivers a more automated, content-rich dashboard for clinicians with important contextual data, meaningful insights and clinical signals that are frequently missed or not measured. Contact: Srirama Venkataraman, Ph.D. Chief Innovation Officer srirama.venkataraman@respondhealth.net reVision Therapeutics, Inc. reVision Therapeutics is a preclinical pharmaceutical company seeking to rapidly develop innovative medicines for ophthalmic disorders through repurposing. Repurposing existing drugs allows the company to reduce development time and cost and lowers manufacturing and safety risks. Our lead program, REV-0100, repurposes a GRAS cyclodextrin as a treatment for Stargardt disease (STGD), a retinal degenerative disease that often begins in childhood. REV-0100 also has promise for treating early dry AMD. A second product candidate, REV-0200, is a repurposed topical ophthalmic product for preventing or treating corneal scarring. Contact: Paul Fehlner, Ph.D., JD Co-Founder, President & CEO pfehlner@revisiontx.com Ricovr Healthcare Ricovr Healthcare is transforming point-of-care (POC) diagnostics with its revolutionary XALIVA™ platform device. With a trend towards personalized medicine, telehealth, chronic disease management and the emergence of new infectious diseases, the medical and diagnostic fields are increasingly turning to POC solutions. Although applicable for other media, including blood and urine, our focus is on using saliva due to its non-invasive collection, high accessibility and potential to provide real-time monitoring of disease markers. Ricovr is commercializing its proprietary plasmonic fiber-optic absorbance biosensor (P-FAB) technology to build an ultrasensitive, portable and low-cost platform reader device while developing diagnostics for high-priority biomarkers. Contact: Himanshu Bhatia, MBA CEO himanshu.bhatia@ricovr.com SATOR Therapeutics SATOR Therapeutics is an oncology company that is focused on the development of oncolytic viruses that are able to selectively kill cancer cells and secondarily illicit a natural immune response. SATOR has developed a library of 30 oncolytic viruses which have demonstrated a differential response across multiple cancers where several viruses have shown efficacy across multiple indications. The viruses are nonengineered, non-pathogenic and can be administered systemically via IV. These viruses were collected over decades of research and by combining them can overcome many of the challenges associated with a single oncolytic virus and neutralizing antibodies while avoiding the safety problems associated with engineered viruses. Contact: Michael Johnson, Ph.D. CEO michael.johnson@satortherapeutics.com
24 EMERGING COMPANY PRESENTER PROFILES Sen-Jam Pharmaceutical Sen-Jam Pharmaceutical repurposes small molecules to bring innovative anti-inflammatory solutions to Patients fast for large unmet needs. Our unique approach allows our products to be used alone or in combination with existing drugs to increase efficacy. Our three lead assets include products for COVID-19, opioid use disorder and an OTC product for the prevention of alcohol hangover, and alcohol’s toxic effects. We are raising $10M to bring our three lead products to the completion of Phase 2, and to develop an injectable formulation. Contact: Jackie Iversen, RPh, M.S. Founder & CCO jackie@sen-jam.com SFA Therapeutics, Inc. SFA Therapeutics has a major vision: to change the way that autoimmune diseases are treated, by replacing immunosuppression with treating the root cause of disease. We have discovered seven drugs, have two FDA INDs, and are running clinical trials in psoriasis and NASH/Fibrosis. We have nine patents through 2038 and are in Phase 1B. We are raising a Series A to fund Phase 2 in psoriasis and autoimmune disease. Contact: Jim Kirwin Chief Operating Officer jameskirwin@sfatherapeutics.com Somnia Therapeutics Somnia Therapeutics is revolutionizing the treatment of obstructive sleep apnea (OSA) with an oral drug alternative to intrusive devices and surgical procedures now available. The unappealing nature of current solutions essentially render OSA an unmet medical need affecting 13 million Americans. Somnia’s drug has encouraging clinical efficacy results in its preliminary proof-of-concept studies with diagnosed OSA Patients and has secured two U.S. patents. Somnia’s total U.S. market opportunity is conservatively estimated to be $4.7 billion. Somnia’s founders are experienced biotech veterans with a proven track record of success. Somnia is raising funds for formulation development and its clinical trials. Contact: Jim Fan, Ph.D. CEO, Chief Scientific Officer & Co-Founder jfan@somniatx.com Starpax Biopharma, Inc. Starpax has conceived an unprecedented platform technology intended to treat cancer using its living self-propelled Magnetodrones that are sensitive to magnetic fields and transport approved anticancer drugs attached to their surface. The Magnetodrones are injected directly into the tumor. Their trajectory is controlled by the Starpax PolarTrak that generates precision 3D guidance monopole magnetic field vectors in order to keep them captive in a tumor and force them to spread and release the anticancer drug throughout the volume of the tumor without circulating in the blood system, avoiding side effects usually resulting from systemic cancer treatments. Contact: Michael Gareau President & CEO mgareau@starpaxmedical.com
25 EMERGING COMPANY PRESENTER PROFILES Tactical Therapeutics, Inc. Tactical Therapeutics, a private company in New York, is developing Carboxyamidotriazole Orotate (CTO) to treat undruggable solid cancers and glioblastoma (GBM). In three Phase I trials, CTO was safe and overcame resistance seen as durable stable disease in 44 undruggable solid cancers. Combined with temozolomide CTO showed brain penetration, Proof-of-Concept in 27 recurrent GBM Patients. Combined with chemoradiation and adjuvant temozolomide in 15 nGBM, CTO significantly improved OS (28 months+) even in resistant mutations (IDHwt, MGMT-ve, EGFR). Randomized Phase II trials of rGBM and nGBM Patients are planned on Orphan Fast Track. Intellectual property is strong lasting to 2037. Contact: Rashida Karmali, Ph.D., JD, MBA CEO & President rashida@tacticaltherapeutics.com Vaneltix Pharma, Inc. Vaneltix is a private, late-clinical phase Urology and Women’s Health Care focused biotech. This market is undergoing a renaissance; however, the innovation engine has not caught up. With two assets in Phase 2b or later, and an interesting preclinical pipeline, Vaneltix is in a unique position to be a serial licensor and or M&A candidate. In addition, our assets are de-risked in many ways, as evidenced by a recent multimillion dollar investment into our lead asset, through royalty financing. We are currently seeking bridge investors to support product development/acquisition and prepare the company for public market opportunities. Contact: Dan Vickery, Ph.D., MBA CEO dan.vickery@vaneltix.com Vetigenics Dogs naturally develop many of the same cancers as people and are now being studied to speed new potential cancer treatments for them and for their humans. Vetigenics, a clinical-stage biotech is devoted to improving the health and well-being of pets by making the life-saving benefits of antibody-based therapies available to treat their cancers and chronic diseases and, by doing so, generate important insights into treating human disease. Our platform technology was created from the the B cells of actual dogs and rapidly generates entirely canine, non-immunogenic antibodies for use as veterinary therapeutics or research reagents canine comparative studies. Contact: Adriann Sax, MBA President & CEO asax@vetigenics.com Vital Start Health Vital Start has developed the first equitable, evidence-based, personalized Digital Therapeutic platform for reproductive and maternity mental health and well-being enabled by Virtual Reality. There are three prongs: 1) COURAGE; a VR/AR platform that allows mental health practitioners and coaches to train their clients (via telehealth) on becoming proficient and experts in stress mitigation techniques and apply them through VR-supported experiential practice, 2) program/care protocols developed by psychologists and mental health experts for self-guided and practitioner-led mental wellness and psychotherapy care leveraging COURAGE capabilities and CognitiveBehavioral Therapy (CBT), and 3) a growing library of copyrighted VR/AR assets for COURAGE use. Contact: Vicki Seyfert-Margolis, Ph.D. Founder & CEO kirthika@vitalstarthealth.com
26 Andson Biotech* Andson Biotech is developing a novel Process Analytical Technology (PAT) platform that is purpose-built for modern bioprocesses and advanced biotherapeutics. Current PATs are a critical bottleneck for scaling advanced biotherapeutics, but Andson’s next-gen sensor platform, DynaPAT, helps unlock this bottleneck by empowering Mass Spec for cell-based processes. DynaPAT leverages our patented microfluidic chip for 1-second sample prep to enable 1) on-demand mass spectrometry for cell-based processes and 2) critical cellstate insights that are currently unavailable. We’re currently piloting with biopharmas, physician scientists and CROs, and we’re seeking additional pilot partners. We are also seeking funding to manufacture, launch and scale DynaPAT. Contact: Mason Chilmonczyk Co-Founder & CEO mason@andsonbiotech.com Ayma Therapeutics Inc. Ayma Therapeutics is an emerging private IND-stage New Jersey-based biotech company. Ayma Therapeutics is developing AYX-101 as a single dose treatment for ARDS Patients suffering from lung injury resulting from acute respiratory distress syndrome (ARDS) and multiple dosing to reduce disease progression to pulmonary fibrosis. AYX-101 consists of triciribine phosphate (TCNP) encapsulated in autologous or allogenic red blood cells (RBCs). AYX-101 is covered by four U.S. issued patents with continuation applications in progress. AYX-101 will be evaluated in additional indications in rare diseases like LAM and cardiovascular areas after successful proof-of-concept in ARDS or CARDS trials. Contact: Ramesh Gopalan, M.Sc., Ph.D. CEO rgopalan@aymatx.com Bestmilk* Bestmilk is a Princeton-based start-up that has developed a groundbreaking technology to extend the shelf life of human breastmilk. The company’s proprietary formula, MilkTabs, uses natural ingredients that work to preserve the quality and nutritional value of human milk, allowing parents to provide the absolute best source of nutrients to their infants longer. Bestmilk’s technology is especially important for working mothers with limited time to breastfeed or pump regularly, as it allows them to store their milk for longer without worrying about spoilage. Bestmilk aims to improve infant nutrition and empower mothers with a safe, effective and easy-to-use-by-parents-anywhere solution. Contact: Katie Silpe Co-Founder jsilpe@princeton.edu BioNanoTech At BioNanoTech, we are on a mission to save lives. Diseases are outpacing drug innovation on a global scale. Biopharma needs proteins, antibodies, large molecules and cells to develop novel drugs but can’t access them efficiently at scale – creating an overlooked $265B dollar opportunity. We have solved this problem. Our revolutionary, size-invariant, ultra-high purity, high-yield protein and antibody purification technology empowers drug discovery and innovation. Currently, biopharmaceutical companies and researchers shelve potential cures if they cannot achieve adequate purity of targeted proteins and antibodies. We turn that waste into cures and profit. Contact: Onyema Osuagwu, M.S., Ph.D. CEO oosuagwu@bionanotech.com START-UPS & INSTITUTION SPIN-OUTS* PROFILES
27 START-UPS & INSTITUTION SPIN-OUTS* PROFILES CorriXR Therapeutics, Inc. Imagine a world in which genetic medicines make immunotherapy, targeted therapy, chemo and radiation more effective, improving outcomes in the treatment of solid tumors. CorriXR is creating this world based on our IP-protected in vivo CRISPR/Cas gene editing platform technology that specifically disables the genomes of tumor cells but not the genomes of surrounding healthy cells. Our initial proof-of-concept focus is to eliminate chemotherapy resistance in squamous cell Non-Small Cell Lung Cancer (NSCLC). Using this platform, we are building a large pipeline of solid tumor targets, including esophageal, head and neck, ovarian, bladder, melanoma, thyroid and pediatric brain cancers. Contact: Eric Kmiec, Ph.D. CEO jkmiec@corrixr.com Dia, Inc. Dia is building the Internet of People. We live in a world where individuals can track their temperature, heart rate and metabolism in real-time, yet the biochemicals that govern key aspects of our health remain unmonitored. Dia aims to revolutionize healthcare by making point-ofcare, noninvasive sensors that measure many molecules critical to mental and physical health. We are starting with the measurement of basic metabolic biomarkers in saliva using a small table-top device. The data can be immediately transferred to a healthcare professional for better monitoring and treatment of the 40+ million Americans living with heart and kidney failure. Contact: Sloane Tilley, M.S., MBA CEO sloane@diasensor.com Endomedix, Inc. Endomedix has developed a novel polysaccharide chemistry platform for biosurgery devices. First platform spinoff is PlexiClot Absorbable Hemostat, targeted initially at brain and spine surgery. PlexiClot provides first fundamental innovation in this sector since 1945. Endomedix will use IP-protected strategic advantages address important unmet needs for this $1.8B market. After establishing a beachhead in neurosurgery, PlexiClot will launch into other surgical markets. A line extension will be introduced for laparoscopy and endoscopy. Endomedix platform is tunable and will produce other biosurgery devices and a battlefield device for U.S. Army. M&A activity in this sector is high. Contact: Richard Russo, MBA CEO rrusso@endomedix.com Haystack Medical* Haystack Medical is developing microneedles and tools for drug delivery into the inner ear, a major challenge that is unaddressed today. Over 30M US patients need a way to cure inner ear disorders – a number that will only grow as the population ages. To date, Haystack has proven its microneedles to be safe and effective in guinea pig and human cadaveric studies. Our technology is supported by 25+ publications and protected by numerous patents and applications. The team has spent a decade developing this technology at Columbia University combining their experience in otolaryngology and surgery as well as in microscale engineering. Contact: Aykut Aksit, Ph.D., M.S., MBA Co-Founder aykut@haystackmedical.com
28 START-UPS & INSTITUTION SPIN-OUTS* PROFILES Innerstill Innerstill is a neurotech company launching non-invasive neuromodulation solutions that balance neuro-hormones essential for every aspect of healthy living. In Q2 2023, the company will launch mindvybetm, a consumer product that simultaneously stimulates auricular acupoints and points along the vagus nerve to alleviate stress and improve general wellness. In 2024, Innerstill plans to submit a 510K application to FDA for addiction recovery using a clinical model of mindvybe, in addition to exploring regulatory pathways for Long COVID treatment. Innerstill will also request FDA pre-sub meetings for their non-invasive deep brain stimulator using interference current for the attenuation of early dementia. Contact: Ellyn Ito Co-Founder & CEO ellyn.ito@gmail.com Lura Health Lura Health enables non-invasive health monitoring with first-in-class salivary diagnostic wearable sensors. The company has created the world’s first non-invasive continuous health monitoring platform using saliva as a diagnostic fluid, which has the potential to improve clinical outcomes in chronic disease management. Applications include tooth decay, heart disease, chronic kidney disease and diabetes. Contact: Daniel Weinstein President daniel@lurahealth.com Med-Con Technologies Med-Con Technologies is a New Jersey Corporation that has created a mobile application that monitors Patients in clinical trials while providing the clinical team real time data. This application works with on both Android and IOS phones. This application is VIRTUAL DIGITAL PATIENT-CENTRIC and PROMOTES DIVERSITY. In a current multi-county/multi-lingual Phase 2 clinical trial with Bayer AG, they are experiencing over 95% adherence. Our current clients include Bayer AG and Fisher Scientific to name a few. We are seeking additional funding to create some additional enhancements for our application. Contact: Anthony Londino President anthony@medcontech.com MetasTx, LLC The MetasTx platform is based upon P21 activated kinase, which plays a crucial role in cancer cell Initiation, Proliferation and Metastasis. MTX-101, a patented, plasma stable, liposomal formulation of IPA-3, a highly selective allosteric inhibitor of PAK-1 has been demonstrated to be effective and safe in several in vivo models of breast and prostate cancer. IND-enabling studies should begin Q2-2023, and our FIH by Q1-2025. MetasTx will focus on discovery, development and early stage clinicals; partner for later clinicals, commercialize through licenses and exit through acquisition. We’re a highly entrepreneurial team with engaged advisors who share a vision to defeat cancer. Contact: Harvey Homan, Ph.D., MBA CEO harveydhoman@metastx.com
29 START-UPS & INSTITUTION SPIN-OUTS* PROFILES Modal Technology Corporation Modal Technology Corporation partnered with McGill University Health Center Research Institute to create Exegis, a new company aimed at merging Modal Technology Corporation’s innovative artificial intelligence technology, ALiX™, with medicine. ALiX, a unique AI solution, provides a ranking of biomarkers based on set theory, not statistics; this is not currently available in any other AI programs. Alix identified a blood-based biomarker profile in the area of metastatic disease that can diagnose Patients and predict response to treatment. Products include 1) A service to generate ranked biomarker profiles with ALiX and 2) Commercialization of a blood-based oncology point of care lab kit. Contact: Susan Kaplan, MAS Executive Vice President & Chief Medical Officer susan@modal.net Myoptechs Myoptechs is developing a soft contact lens that slows the progression of myopia, thereby helping reduce the short- and long-term vision implications of the disease. Contact: Paul Grimm CEO pgrimm@myoptechs.com NemaGen Discoveries* NemaGen Discoveries is a New Jersey-based, early phase biopharmaceutical company that is advancing therapies for Patients suffering from allergic, mast cell-related and inflammatory diseases. NemaGen Discoveries was founded in 2019 by Dr. Mark Siracusa, based on research from his laboratory at Rutgers University. Contact: Nick Shubin, Ph.D. CEO nick.shubin@nemagen.com New York Medical College The activity of this business is primarily to commercialize inventions developed at New York Medical College and create new jobs for the benefit of society. More specifically, NYMC Biotechnology Commercialization LLC acquired the rights to an invention entitled “Bandage with Microneedles for Antimicrobial Delivery and Fluid Absorption from a Wound.” This is one of the many new patents to be developed at NYMC’s biotechnology incubator, BioInc@NYMC. NYMC recently reached an agreement to acquire a world-class portfolio of patents in medical, technological and consumer products with one of the world’s most prolific inventors. Contact: George Young, MBA Manager, Office of Research gyoung8@nymc.edu
30 START-UPS & INSTITUTION SPIN-OUTS* PROFILES Notitia Biotechnologies Company Notitia Biotechnologies develops microbiome-based therapeutics to address unmet medical needs. Their proprietary technologies can identify, promote and culture the Foundation Guild, a group of beneficial gut bacteria crucial in structuring and stabilizing gut microbiota. The Foundation Guild can be transplanted with targeted nutritional support using the investigational drug NBT-NM108, which has shown promising results in Phase 2a clinical trials and expanded access cases. The unique Foundation Guild Transplantation (FGT) platform aims to revolutionize the treatment of unmet medical needs by providing a new generation of microbiome therapeutics centered on the Foundation Guild bacteria. Contact: Jeffrey Zhao Co-Founder & CEO jeffrey.g.zhao@notitiabio.com Omnitia Therapeutics* Omnitia Therapeutics is developing first-in-class drugs for the treatment of neurodegenerative disorders. Primary indications include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP). Based on foundational technologies from leading laboratories at Columbia University and Harvard Medical School, the company has developed proprietary small molecules and nucleic acid-based approaches that leverage the cellular stress response to inhibit pathological protein aggregation. Beyond neurodegenerative disorders, Omnitia’s technologies are relevant to several indications in oncology and virology, with positive preclinical data in these programs as well. The company expects its first assets to enter clinical trials within 18-24 months. Contact: Joseph Rayman, Ph.D. Co-Founder & Chief Scientific Officer jbr2114@columbia.edu Robossis, Inc.* Robossis will be the first commercially available surgical robotic system to align long-bone fractures in the large and growing orthopedic medical device market. Robossis enables the surgeon to accurately apply large traction forces, precisely align the fractured bone and significantly reduce x-ray radiation. The system consists of a surgical robot, imaging software and a haptic controller. Over 430,000 femur fractures occur in the U.S. annually. Our target market is $2.2B consisting of 885 high-volume hospitals in the U.S., each performing more than 280 surgeries per year. Contact: Mohammad Abedin-Nasab, M.S., Ph.D. Founder & CEO abedin@rowan.edu Sauvie, Inc.* Sauvie is a mission-driven biopharmaceutical company focused on sustainably building a premier immuno-oncology company. The name Sauvie has been derived from a French sentence “sauver une vie” which means “to save a life.” Sauvie was formed to embody this meaning in what we do with a vision to save lives by curing the diseases we treat. Contact: Ken Suh, MBA CEO ksuh@sauvieinc.com
31 START-UPS & INSTITUTION SPIN-OUTS* PROFILES SciMar ONE, Inc.* SciMar ONE is a New Jersey-based, woman-owned technology company enabling the biopharmaceutical industry to accelerate drug development and help get life-changing therapies to Patients faster. SciMar provides the first comprehensive suite of products addressing Development Velocity™ (DV™), the speed a biopharmaceutical company moves a new therapy through the drug development process and into the market. SciMar’s proprietary scoring methodology, the DV Index™, identifies specific bottlenecks slowing drug development and its AI-powered cloud-based SaaS technology, the DV Platform™, replaces those inefficiencies to modernize drug development’s manual process and accelerate therapies to market. Contact: Donna Conroy CEO donna@scimarone.com See-Me, Inc. 47% of U.S. Healthcare Professionals (HCPs) may leave medicine in the next 2-3 years due to burnout! See-ME (see-me.pro) is the first Mobile-First Platform that aims to support HCPs by simplifying the administrative burden of CME & Med-ED maintenance, facilitating engagement through Trusted Networks & Collaborators and encouraging professional development through the Business of Medicine. Contact: Najur Runganadhan CEO najur.runganadhan@see-me.pro Sonavi Labs* Sonavi Labs is on a mission to improve Patient outcomes globally by harnessing the most advanced acoustic technology available coupled with clinically proven diagnostic AI software. Sonavi Labs was formed to deploy Feelix, a chronic disease management system that features patented hardware embedded with clinically validated diagnostic software designed to support clinicians in detecting and monitoring respiratory diseases. The Feelix system also features supportive apps and an integrated cloud platform to provide remote monitoring solutions for chronic disease Patients with asthma, COPD and Cystic Fibrosis, along with being an ideal solution for enhancing telehealth visits. Feelix is the world’s first digital stethoscope that can be used by clinicians and Patients anywhere. Contact: Ellington West Co-Founder & CEO ellington@sonavilabs.com Vitranu, Inc. Vitranu is developing a Tunable Extended-Release Capsule (TERC) for biologic pharmaceuticals and small molecules delivered via intravitreal injection to treat eye diseases, including Age-related Macular Degeneration. The company uses novel electrospinning technology to produce a tiny, biodegradable, tunable capsule that can be filled with either biologic or small molecule therapeutics. By altering the electrospinning process parameters, capsules can be made with defined pore sizes and “tuned” to deliver the payload with the desired drug elution over time. This patent-pending and unique approach provides a platform technology to fulfill the unmet need of sustained drug delivery. Contact: Gordon Bethwaite CEO gordon.bethwaite@icloud.com
32 START-UPS & INSTITUTION SPIN-OUTS* PROFILES WatchRx, Inc. WatchRx offers a smartwatch-based solution to help seniors take medications on time, live independently with dignity. The smartwatch app provides personalized visual medication reminders with name, image and dosage, built-in phone, live GPS tracking and AI voiceassistant helpline. Our caregiver app for family caregivers and care coordinators gets smart alerts in real-time for preventive actions. Using our AI-based Care Coordination platform, we provide remote Patient monitoring (RPM), chronic care management (CCM) and transitional care management (TCM) services. Our AI Analytics solution helps hospitals and physicians deliver quality care to Patients, improve Patient outcomes, lower healthcare costs and reduce hospitalizations. Contact: Jayanthi Narasimhan, M.S. Founder & CEO jayanthi0307@watchrx.io XN Health XN Health is a medical device company focused on preventing Ventilation Induced Diaphragm Dysfunction (VIDD) – a condition induced by mechanical ventilation which hinders Patients from breathing independently. Our novel technology stimulates the phrenic nerves which are responsible for contracting the diaphragm, the primary respiratory muscle, which rehabilitates the muscles of these fragile Patients. Contact: Elizabeth Jaworski, Ph.D. CEO elizabeth@xn-health.com
33 INNOVATION INSIDER SPONSOR VISIONARY’S VIEW SPONSORS PARTNERING SPONSOR AWARD SPONSOR PRESIDENT SPONSORS EXHIBIT SPONSORS THANK YOU TO OUR SPONSORS MEDIA SPONSORS
34 SPONSOR PROFILES Amicus Therapeutics Amicus is a global, Patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. Amicus is the Latin word for friend. This name signifies our collaborative approach to developing medicines by incorporating the patient perspective every step of the way. By championing mission-dedication, innovation, performance and integrity, we are united by our passion for making a difference and committed to pushing ideas as far and as fast as possible. August eTech August eTech is an information technology consulting company that specializes in working with the life sciences industry to ensure that their technology solutions meet regulatory and compliance standards, such as GxP, FDA 21 CFR Part 11, HIPAA, and cybersecurity. We offer a range of services, including consulting CIO services, pen testings and Managed Service Provider offerings, to help our clients design, deploy and manage secure technology solutions that meet their needs and comply with regulatory requirements. August eTech also works closely with our clients to help them build a budget that takes into account their technology goals and compliance obligations. Center for Breakthrough Medicines Center for Breakthrough Medicines (CBM) is a cell and gene therapy contract development and manufacturing organization (CDMO) uniquely positioned to enable pharma and biotech companies to develop, test and manufacture life-saving therapies and treatments on a global scale. Ideally located in the heart of Philadelphia’s Cellicon Valley, CBM has assembled the most accomplished cell and gene therapy experts in the world, armed with cutting-edge and innovative technologies, to offer scalable, best-in-class pre-clinical through commercial manufacturing capabilities, including process development, plasmid DNA, vector manufacturing, cell banking, cell processing and a full suite of complementary and standalone testing and analytical capabilities. Centri Consulting Centri Business Consulting provides the highest quality advisory consulting services to its clients by being reliable and responsive to their needs. Centri provides companies with the expertise they need to meet their reporting demands. Centri’s seasoned team will guide you through the financial reporting and compliance challenges of the life sciences industry. We offer customized life sciences accounting services designed to meet the demands of your company as they emerge and evolve. From going public to expanding your product portfolio and everything in between, we can help you anticipate and overcome any obstacle. CFGI CFGI, a portfolio company of Carlyle and CVC, is the nation’s largest non-audit accounting advisory firm. CFGI supports the Office of the CFO and Private Equity Sponsors with all your critical finance and accounting operations. We deliver the people, processes and technology solutions to solve all your operational finance, technical accounting and risk management challenges. Learn more at www.cfgi.com. Circular Edge Circular Edge consulting services provide clients with the tools they need to succeed in today’s fast-paced business environment. We specialize in JD Edwards, NetSuite and Oracle EPM consulting, offering customized solutions to meet the unique needs of each client. Our team of experts has years of experience working with these powerful business management systems, and we’re dedicated to helping our clients get the most out of them. From implementation to optimization, our consulting services cover every aspect of these platforms, providing companies with the knowledge and support they need to make informed decisions and achieve their business goals. Choose us for business consulting that will help you take your business to the next level. CohnReznick For a life sciences company, ongoing innovation, access to capital and the ability to obtain regulatory approval are the cornerstones for success. Improving operational, financial and risk management practices as you grow enhances your ability to attract investors, commercialize and exit when the time is right. CohnReznick’s Life Sciences Industry specialists serve as trusted accounting, tax and business advisors to assist you in making critical go-forward decisions. For more information, contact Ravi Raghunathan at ravi.raghunathan@cohnreznick.com or 973-364-7826. DLA Piper DLA Piper is a global law firm with lawyers located in more than 40 countries throughout the Americas, Europe, the Middle East, Africa and Asia Pacific, positioning us to help clients with their legal needs around the world. We strive to be the leading global business law firm by delivering quality and value to our clients. We achieve this through practical and innovative legal solutions that help our clients succeed. We deliver consistent services across our platform of practices and sectors in all matters we undertake. Our clients, among them life sciences clients, range from multinational, Global 1000 and Fortune 500 enterprises to emerging companies developing industry-leading technologies.
35 SPONSOR PROFILES EisnerAmper EisnerAmper’s Life Sciences Practice professionals have the expertise, resources and relationships to assist both public and private life sciences companies bridge the gap between business and science. In addition to traditional tax and accounting services, EisnerAmper assists our life sciences clients with technology, corporate finance and IPO readiness services. For more information, visit us online at www.eisneramper.com/life_sciences and explore our thought leadership resource library at www.eisneramper.com/knowledge-center. Foundation Venture Capital Group Foundation Venture Capital Group uses impact investing to provide pre-seed and seed funding to health-related start-up companies at Affiliated Organizations to help them advance toward and through commercialization. Our investments are made to generate positive, measurable social impact with any gains realized from the investments reinvested into furthering research and innovation at our Affiliated Organizations. J.P. Morgan J.P. Morgan Life Sciences bankers are dedicated to delivering financial solutions tailored to your needs. From early stage start-ups to multinational corporations, we understand the unique challenges life sciences companies face at every stage of their life cycle. The pace at which life sciences companies move from proof of concept to commercialization is accelerating, and J.P. Morgan offers a unique platform with which your company can grow. Our national footprint enables us to provide access to vital industry networks and leverage firm-wide expertise while helping guide your company as it navigates the regulatory environment and FDA approval process. For more information, contact Kathleen Addison, Executive Director, Life Science at Kathleen.addison@jpmorgan.com. Johnson & Johnson Innovation Our mission is to unlock the potential of life sciences innovation no matter where it originates. Johnson & Johnson Innovation Teams aim to solve the world’s toughest health challenges and drive scientific breakthroughs that improve health for everyone, everywhere. We know that a great idea can come from anywhere and we are proud of our strong track record of cultivating innovation and pairing our deep internal know-how with some of the most promising external innovation from around the globe. Marcum Marcum LLP is a national accounting and advisory services firm dedicated to helping entrepreneurial, middle-market companies and high net worth individuals achieve their goals. Since 1951, clients have chosen Marcum for our deep expertise and insightful guidance in helping them forge pathways to success, whatever challenges they’re facing. Marcum offers a complete spectrum of tax, assurance and advisory services, with specialized expertise for both privately held and publicly registered companies. The firm also provides a full complement of technology, wealth management, executive search and staffing services. Merck Merck has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. From Merck’s development of the first measles and mumps vaccines to treatments for cancer and diabetes, we are an industry leader in bringing forth innovative new medicines. We recognize that building partnerships is one of our most important jobs. In 2022, more than half of our human health revenue was attributable to acquisitions, alliance partnerships and patents and our team executed 97 significant business development transactions. We believe that by working together we can play a major role in transforming global health care. www.merck.com/licensing. Middlesex County The Office of Business Engagement (OBE) is the key connector and partner for market-leading companies and innovative entrepreneurs seeking to relocate, expand or start-up in Middlesex County, NJ. With a focus on enhancing the County’s nationally recognized ecosystem for life sciences, food innovation and autonomous technology industries, the OBE, together with the business community, is charting the County’s path in the next normal. The OBE offers assistance in a range of areas including workforce development, site selection and the entitlement process, and facilitates introductions to key local leaders to enable a seamless transition, operation and sustainable growth. Morgan Lewis With more than 400 lawyers who focus on the life sciences industry, Morgan Lewis has one of the most comprehensive practices in this area. We are unsurpassed in our global understanding of the business, regulatory, intellectual property, litigation and related issues that our clients face along the product life cycle, from innovation and emerging business issues, through research and development, regulatory approval, product reimbursement, marketing and distribution, to fraud and abuse, product liability and intellectual property litigation, to mergers and acquisitions, collaborations and outsourcing. Our team expands across the U.S. with capabilities in Europe, Asia and the Middle East. The breadth of our industry clientele includes large and mid-size pharma and biopharma, emerging biotechnology, medical device, food and nutritional supplements, wholesalers and distributors, research and scientific institutions and venture capital and private equity funds focused on the industry.
36 New Jersey Economic Development Authority (NJEDA) The New Jersey Economic Development Authority (NJEDA) grows the State’s economy and increases equitable access to opportunity by supporting high-quality job creation, catalyzing investment and fostering vibrant, inclusive community development. NJEDA works in partnership with a diverse range of stakeholders to implement programs and initiatives that improve quality of life, enhance economic vitality and strengthen New Jersey’s long-term economic competitiveness. Novartis Located in East Hanover, NJ, Novartis Pharmaceuticals Corporation – an affiliate of Novartis – is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis employs nearly 14,500 people in the United States. For more information, please visit www.novartis.us. Princeton Innovation Center BioLabs Princeton Innovation Center BioLabs, a premier incubator for technology and life sciences start-ups in New Jersey, is a 30,000 square-foot facility that offers wet and dry labs, private offices and open co-working space for start-up companies with transformative technologies that are interested in a collaborative environment. The members of Princeton Innovation Center BioLabs have access to our shared lab equipment, EH&S and hazardous waste services and a convenient purchasing platform. We also offer educational events and networking opportunities for entrepreneurs and innovators. PsychoGenics PsychoGenics’ AI-enabled drug discovery platforms SmartCube®, NeuroCube®, PhenoCube® and eCube® and their diverse CNS active compound library support internal programs and shared-risk partnerships with major pharmaceutical companies (including Sunovion, Roche and Karuna), and have supported the development of multiple novel compounds that are in advanced preclinical development or in clinical trials. This includes the discovery of ulotaront, in partnership with Sunovion, which is in Phase III clinical trials for the treatment of schizophrenia, depression and anxiety, which could be the first approved novel drug discovered using AI. RSM US RSM US LLP (“RSM”) is the nation’s leading provider of audit, tax and consulting services focused on the middle market and is the U.S. member of RSM International, a global network of independent audit, tax and consulting firms with 51,000 people across 123 countries. From our office in Metro Park, we service the life sciences and biotech industries and the New Jersey community at large. RSM uses its deep understanding of the needs and aspirations of clients to help them succeed. For more information, visit rsmus.com, like RSM on Facebook, follow RSM on Twitter and connect with RSM on LinkedIn. SciSafe SciSafe offers dedicated Pharmaceutical and Biological Specimen Storage in its fully cGMP compliant state of the art facilities all ISO 9001/ ISO 20387, FDA registered and inspected since 2011 (CDER & CBER), with 86+ (SOP’s) all modeled after FDA (21 CFR parts 210 & 211). We store at temperatures between -196°- 40˚C. The types of samples we store include: Reagent storage & fulfillment, cell line, compound libraries & mirror banking, pre-clinical research & trials, clinical trial storage with patient efficacy testing, DNA storage & fulfillment, Vaccines, CAR-T & immunotherapy, bulk materials, drug substance and biological ingredients. In addition, we can provide all types of customized solutions. TCG GreenChem TCG GreenChem was conceptualized by Dr. Chris H. Senanayake and Dr. Joseph D. Armstrong, Ill, former pharmaceutical executives with a track record in the development of hundreds of New Chemical Entities into the clinic and commercialization of several well-known pharmaceutical products. The senior leadership brings the experience, technological expertise and know-how, which is required to manufacture architecturally complex intermediates and APls by utilizing state of the art synthetic organic chemistry and cutting-edge technology platforms such as catalysis and continuous flow chemistry. TCG GreenChem is positioned as a contract innovation company that provides CDMO services with a unique modus operandi in the space of supporting pharmaceutical R&D. Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $45 billion and approximately 125,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve Patient diagnostics, deliver medicines to market and increase laboratory productivity. For more information, please contact Kristin Roosevelt at kristin.roosevelt@thermofisher.com, or 610-453-0370. SPONSOR PROFILES
37 Withum + Brown, PC Withum is a forward-thinking, technology-driven advisory and accounting firm committed to helping life sciences companies navigate the fastpaced, dynamic environment regardless of their current life cycle or stage of development. With offices in major cities and financial centers across the country, and as an independent member of HLB, the global advisory and accounting network, we support businesses across the country and from around the world. We offer innovative solutions to help public and private life sciences companies achieve their goals. Get to know us at www.withum.com/lifesciences or contact Taryn Bostjancic at tbostjancic@withum.com for more information. Worldwide IP Solutions Innovation and commitment to rapid technology development may fuel your company’s growth, but your competitive edge is dependent on a solid strategy for protecting your intellectual property. Without these safeguards, your company’s commercial and financial value is vulnerable to infringement and devaluation. At Worldwide IP Solutions, we specialize and understand the nuances vital to the management, protection and enforcement of intellectual property around the world. WIPS is an invaluable resource for organizations all around the globe. SPONSOR PROFILES Helping Our Members Help Patients As New Jersey’s life sciences trade association, our nearly 400 Members represent the full life sciences ecosystem – from research-based innovation companies, academia and Patient advocacy groups to economic development organizations and service providers. As a BioNJ Member, your entire Team can take advantage of the many opportunities and benefits that are available through Membership. Acts as a conduit for idea sharing, learning, collaboration and mentorship through its many networking and educational programs Provides an extended marketing arm, offering a platform to showcase your science, services and organization to a broad network Advocates in both Trenton and Washington D.C. to ensure that government fosters medical innovation and Patient access Works with policymakers to secure incentives and programs that allow New Jersey’s innovation ecosystem to flourish Provides deep savings through our Purchasing Consortium so Member companies can preserve their working capital Offers numerous business-building tools, such as BioNJ’s Talent and Career Portal BioNJ... For more information on BioNJ Membership, please contact Cheri Hennessy at CHennessy@BioNJ.org or call 609-890-3185.
38 ATTENDEE LIST Name Job Title Company Mohammad Abedin-Nasab Founder & CEO Robossis, Inc. Alexis Acker Business Development Worldwide IP Solutions, LLC Kathleen Addison Executive Director, Life Sciences J.P. Morgan Chase Bank, NA Aykut Aksit Co-founder & CEO Haystack Medical Sally Allain Head, JLABS Johnson & Johnson (Janssen) Scott Alpizar Director, Venture Commercialization New Jersey Health Foundation/Foundation Venture Capital Group Jay Amin Academic Scholar Rutgers Business School Parsa Amiri Naeini Startup Management Associate Endless Frontiers Lab | Life Sciences Startup Accelerator Rene Anand CEO & Founder Neurxstem, Inc. John Anthes Sr. Director Integrative Sciences Bristol Myers Squibb Alexander Antonopoulos Managing Partner The Money Channel NYC Andrew Apicello Vice President, Business Development PlanetConnect Jason Apter CEO Sannova Analytical Treena Arinzeh Professor, Biomedical Engineering Columbia University Joseph Armstrong Chief Operating Officer TCG GreenChem, Inc. Manish Arora Co-Founder & CEO LinusBio Monika Athwal Sr. Product Officer Innovation Programs New Jersey Economic Development Authority (NJEDA) Michael Atkin CEO Syzent Partners, LLC Ingrid Austin PR & Communications Manager Choose New Jersey Lina Axanova Sr. Associate Director, Perelman School of Medicine University of Pennsylvania Albert Baker Corporate Director Hackensack Meridian Health Andy Bala Founder & CEO Delphine Diagnostics, Inc. Erika Ballo Manager EisnerAmper, LLP Joshua Barer Managing Director Hibiscus Capital Management James Barry Executive Director, Business Development EVERSANA Melissa Bastan Industry Manager - Healthcare & Higher Education JP Morgan Chase Bank, NA Jay Batchu Entrepreneur in Training Xontogeny Mark Baum Angel Investor JumpStart NJ Angel Network James Beare Executive Director - Treasury Sales Group Manager J.P. Morgan Chase Bank, NA Simon Beaulah Sr. Vice President Healthcare PrecisionLife Bob Bell ERP Director Archer Insights April A. Benasich Co-Founder & Chief Scientific Officer RAPT Ventures, Inc. (RVI) Dan Benderly Associate Director, New Ventures Rutgers, The State University of New Jersey Sam Bergen Vice President Frontcourt Group Ryan Berman Senior Manager EisnerAmper, LLP Jacqueline Berman Partner Morgan Lewis Nicollete Bernardino Account Executive, Life Sciences Staffing Resource Group Eric Bernbach Client Relationship Executive CohnReznick, LLP
39 ATTENDEE LIST Name Job Title Company Olga Berson Partner Morgan Lewis Gordon Bethwaite CEO Vitranu, Inc. Amit Bhalla Chief Financial Officer Sampled Pooja Bhandari Director, New Products and Business Development, Hematology Johnson & Johnson (Janssen) Himanshu Bhatia CEO Ricovr Healthcare Jay Bhatti Co-Founder 49 Alpha Anthony Birritteri Editor-in-Chief New Jersey Business Magazine Alexis Blacknik Marketing Coordinator WithumSmith+Brown, PC Alfred Blaikie Chief Business Development Officer The Money Channel NYC Stefano Blanco Sales Representative Thermo Fisher Scientific David Bleakman President, Drug Discovery & Development PsychoGenics, Inc. Melina Blees Site Director BioLabs Philadelphia Greg Bosch CEO Panavance Therapeutics, Inc. Taryn Bostjancic Partner, Practice Leader, Life Sciences Services WithumSmith+Brown, PC Mark Boulding Executive Vice President & Chief Legal Officer PTC Therapeutics, Inc. Robert Bowden Senior Director Janssen Pharmaceuticals Jeff Bowley Managing Director Centri Business Consulting Michael Boyce-Jacino CEO Aptatek BioSciences, Inc. Luis Branco Laboratory Equipment Representative Thermo Fisher Scientific Rich Brandwein Chief Technology Officer PlanetConnect Gary Branning Professor, Pharma Management & President Rutgers Business School & Managed Market Resources Dan Brettler Senior Partner Conner Strong & Buckelew Chad Brown Executive Director, Pharmaceutical Sciences Merck Animal Health Eric Broyles Founder & CEO Nanocan Therapeutics Corporation Michael Bruckman CEO Haima Therapeutics Steve Brugger Industry Consultant and Advisor SBB, LLC Lauren Brzozowski Spokesperson Worldwide IP Solutions Bob Bullard Assistant Vice President, Professional Success Rowan University Ross Bundy CEO CRISPR QC Bridget Burke Chief Business Officer Slone Partners Sharon Burns Commercial Marketing Manager SciSafe, Inc. Gayle Burstein-Teitelbaum Contract Manager Janssen Research & Development, LLC Samuele Butera President, Janssen Pulmonary Hypertension & Retina Janssen Pharmaceuticals Dana Callow Managing General Partner Boston Millennia Partners Tatiana Canessa Innovation Activation Manager JLabs Thomas Cantwell Partner Marcum, LLP Mario Casabona Founder & CEO Casabona Ventures, LLC Sandy Castor Director Office of Business Engagement, Middlesex County
40 ATTENDEE LIST Name Job Title Company Jessica Catapano Director Tandym Group Cortney Cavanaugh New Ventures and Licensing Associate Princeton University Ahmet-Hamdi Cavusoglu Program Director Merck Digital Sciences Studio Prathik Chandrasekaran Vice President, Life Sciences J.P. Morgan Chase Bank, NA Ernesto Chanona Vice President, Business Development & Government Affairs CSSi LifeSciences Paresh Chaudhari Director, HEOR Indegene, Inc. Lillian Chiang CEO Evrys Bio Mason Chilmonczyk CEO & Co-Founder Andson Biotech Laura Chittick Managing Director J.P. Morgan Chase Bank, NA David Chung Chief Business Officer Avistone Biotechnology Co. Ltd. Guadalupe Cipres Partner Trillium Medical Ventures Steven Cohen Partner, Chair Emerging Business & Tech Practice Morgan Lewis Elaina Coletta Managing Director CFGI Clayton Collins Vice President, Financial Advisor Morgan Stanley Lauren Conigliaro Financial Advisor Morgan Stanley Dan Conley Managing Director Angels + Life Sciences Investors Network Melissa Conner Sr. Director, Trans Oncology Acquisitions Janssen R&D Mitzi Conners Executive Director, & Head of Ops, BD & Licensing Merck & Co., Inc. Donna Conroy CEO & Founder SciMar ONE, Inc. Heather Cosimano Business Development Manager FARRAR / Trane Technologies Kathleen Coviello Chief Economic Transformation Officer New Jersey Economic Development Authority (NJEDA) Scott Cowan Partner DLA Piper, LLP Christopher Cozic Chief People Officer Genmab Philip Crowley Principal Crowley Law, LLC Katelyn Crowley-Lum Business Development Executive WithumSmith+Brown, PC Herm Cukier CEO Enalare Therapeutics, Inc. Steve Czarnecki Associate Principal WB Engineers+Consultants Warren Czerniak President Gedeon Richter USA, Inc. Jennifer Daugherty Global Enterprise Relationship Lead Fisher Scientific John Davan Chief Financial Officer Hepion Pharmaceutics, Inc. Subhajyoti De Associate Professor Rutgers University Christina Deaver Executive Director, Asset & Wealth Management J.P. Morgan Chase Bank, NA Lexie Demirali Senior Product Officer, North New Jersey Economic Development Authority (NJEDA) Michael Demurjian CEO Aspargo Laboratories, Inc. William DeStefano Vice President, Life Science Practice Marsh, Inc. Annie Devine Senior Vice President Marsh, Inc. Amadou Diarra Sr. Vice President, Global Policy, Advocacy & Government Affairs Bristol Myers Squibb Jackson Diaz-Cobo Executive Director - Healthcare Services J.P. Morgan Chase Bank, NA
41 ATTENDEE LIST Name Job Title Company Veronica DiCamillo Counsel Morgan Lewis Anthony DiGiacinto Director EisnerAmper Tony Dimun Founding Partner Nascent Enterprises, LLC Shailja Dixit CEO & Founder Curio Digital Therapeutics Alyssa Doecks Sales Representative Fisher Scientific Company, LLC Dylan Dsa Sales Development Representative UL Solutions Dean Edelman Senior Associate Director Princeton University Mahako Etta Program Manager New Jersey Commission on Science, Innovation and Technology William Evans Executive Director, Major Giving - CDI Hackensack Meridian Health Andrew Evens Associate Vice Chancellor Rutgers Cancer Institute of New Jersey Jim Fan Co-Founder, Interim CEO & Chief Scientific Officer Somnia Therapeutics, LLC Matt Fazelpoor Reporter NJBIZ Paul Fehlner Co-Founder, President & CEO reVision Therapeutics, Inc. Jonathon Fendelman Sr. Director, Global Business Development Pharming Group Nigel Fernandes Sr. Director, Business Development Emerald Cloud Lab Albert Fetaya Head, US Business Development Servier Pharma Aaron Fichtner President New Jersey Council of County Colleges Suzanne Filippi Partner Morgan Lewis Stan Filippin Business Development Biomedica Group Robert Fiorentino Life Science Practice Lead Partner Marcum, LLP James Fischer Partner DLA Piper, LLP Paul Fitzsimmons Managing Director, Originations X-Caliber Jim Foote Co-Founder & CEO First Ascent Biomedical Charley Ford Senior Commercial Officer Consulate General in New York - Ontario Trade & Investment Nikki Frazier Senior Relationship Manager Centri Business Consulting Sarah Frey Laboratory Equipment Representative Thermo Fisher Scientific Shao Fu Vice President, Operations Novelstar Pharmaceuticals, Inc. Merle Fuchs Co-Founder & CEO PRAMOMOLECULAR Sarah Fuller Head, Business Development, North America Kyowa Kirin Elissa Fuller Chief Business Officer Reset Pharma Mitchell Fullerton Alliance Manager Columbia University James Gale Managing Director Signet Healthcare Partners John Ganter Risk Advisor CBIZ-BP Michael Gareau Founding President & CEO Starpax Biopharma, Inc. Chris Gartin Managiang Director, Healthcare Investment Banking J.P. Morgan Michael Gemellaro Partner RSM US, LLP Barbara George Johnson Vice President, External Affairs & Urban Policy Kean University
42 Name Job Title Company Sam Giannakoulias Chief Technology Officer Sentauri, Inc. Salvatore Giovine Chief Financial Officer, Pharmaceutical BD & External Innovation Johnson & Johnson Innovation David Glazer Partner Morgan Lewis Amanda Goceljak Partner Morgan Lewis Abram Goldfinger Executive Director, Technology Transfer NYU Daniel Goldman Ph.D. Student in Chemistry Seton Hall University Jim Golubieski President New Jersey Health Foundation/Foundation Venture Capital Group John Gonzaga Associate, Life Science J.P. Morgan Chase Bank, NA Liz Gosen Sr. Vice President, Technical Operations Janssen Pharmaceuticals Amrie Grammer Co-Founder, President & Chief Scientific Officer AMPEL BioSolutions, LLC Dave Greenwood Regional Sales Director Circular Edge Arthur Greyf CEO OsseoPrint 3D Keisha Griffin Exec. Assist., External Affairs & Urban Policy Kean University Paul Grimm CEO Myoptechs, Inc. Lindsey Gross Director, Outsourced Finance & Accounting EisnerAmper, LLP Christopher Guiton Senior Director, US State Government Affairs Johnson & Johnson (Janssen) Jim Gunton Managing Partner Tech Council Ventures Michael Hadjiloucas Partner EisnerAmper Bill Hagaman Partner WithumSmith+Brown, PC Thurston Hamlette Counsel Morgan Lewis Lenzie Harcum Director, NJ Bioscience Center New Jersey Economic Development Authority (NJEDA) Andy Harlan Executive Director, Asset & Wealth Management J.P. Morgan Chase Bank NA James Harris Life Sciences Project Manager, IP New Jersey Department of Labor Jennifer Harrison Division Head, Real Estate Office of Business Engagement, Middlesex County Juliet Hart Principal Hart & Chin Associates, LLC Audrey Haukioja Chief Development Officer Sauvie, Inc. Andrew Haupt Partner Morgan Lewis Eric Heil Managing Partner Medical Excellence Capital George Heinrich Vice Chair & Chief Executive Officer New Jersey Health Foundation/Foundation Venture Capital Group James Heins Senior Vice President & Managing Director LaVoieHealthScience Daniel Hendrickson Senior Director Tandym Group Valentine Henry de Frahan MPH/MBA Student Johns Hopkins University Gerri Henwood President & CEO Baudax Bio Jenny Herbach CEO Adventris Brandan Hillerich Senior Director, Business Development Adiso Therapeutics, Inc. Lori Hollis Principal Orsacon, LLC Scott Holt Business Development Director Fisher Scientific Company, LLC Harvey Homan CEO and Co-Founder MetasTx, LLC ATTENDEE LIST
43 Name Job Title Company Takeshi Hondo Director, Global Open Innov, Corp Strategy Mitsubishi Tanabe Pharma America, Inc. Paul Howard Senior Director, Public Policy Amicus Therapeutics Guanghui Hu CEO NAKI Therapeutics Thomas Hudson CEO RISC ai Socheata Huy Vice President, Treasury Management J.P. Morgan Chase Bank, NA Jesse Hwang Scientific Engagement Lead Johnson & Johnson Innovation Hiroshi Ikeuchi Senior Manager Otsuka Tariq Imam Vice President, Business Development & Operations Lisata Therapeutics, Inc. Brian Imszennik Director, Venture Investments Johnson & Johnson Innovation Michael Ingber Angel Investor Mark Lorio CMO & Co-Founder See.Me Sho Islam Division Head, Life Sciences & Food Innovation Office of Business Engagement, Middlesex County Ellyn Ito Co-Founder & CEO Innerstill Jacqueline Iversen Founder & Head, Clinical Development Sen-Jam Pharmaceutical Jim Iversen CEO Sen-Jam Pharmaceutical Brian Jahns Chief Operating Officer Sauvie, Inc. Ruhee Jain Academic Scholar Rutgers Business School Ariel Jasie Chief Business Officer Manta Medicines Elizabeth Jaworski CEO XN Health Kelly Jeng Venture Associate NJ Health Foundation Terry Johnson Partner Morgan Lewis Michael Johnson CEO SATOR Therapeutics Danielle Johnson Senior Managiang Director Tandym Group Tony Jones CEO One Nucleus Travis Josephs Academic Scholar Baylor College of Medicine Josh Jubilee Sales Representative Thermo Fisher Scientific Ludovit Jurecek Medical Director Biomedica GMBH Andrew Kabatchnick Investor Andrew Kabatchnick, CPA Scott Kachlany Founder & Chief Scientist Actinobac Biomed, Inc. Ronak Kadakia Chief Operating Officer Linus Biotechnology, Inc. Meghan Kaiser Risk Advisor CBIZ-BP Joyce Kamande Assistant Director, Perelman School of Medicine University of Pennsylvania Aman Kant Chief Business Officer Invea Therapeutics, Inc. Avani Kanubaddi President & Chief Operating Officer Enveric Biosciences, Inc. Susan Kaplan Executive Vice President & CMO Modal Technology Corporation Rashida Karmali CEO Tactical Therapeutics, Inc. Lou Kassa CEO Pennsylvania Biotechnology Center Lola Kassim Director, Poeple & Organization Novartis Pharmaceuticals Ana Katsafanas MPH/MBA Candidate Johns Hopkins University ATTENDEE LIST
44 Name Job Title Company John Kaufmann Chief Financial Officer S1 BioPharma, Inc. Syed Kazmi President & CEO Jubilant Therapeutics, Inc. Frances Keel Senior Project Lead New Jersey Economic Development Authority (NJEDA) Yvonne Kemps Senior Project Manager Invest in Holland Josh Kern Assoc. Director, Business Development Transactions Janssen Pharmaceuticals Nina Keshavarzi Founder & CEO Celine Therapeutics Aaisha Khan Senior Marketing Manager Morgan Lewis Nitin Khanna CEO Archer Insights Christopher Kiesel Client Services Manager BioBridges Aidan King Co-Founder & Managing Partner Fountain Healthcare Partners James Kirwin Chief Operating Officer SFA Therapeutics, LLC Eric Kmiec CEO CorriXR Therapeutics, Inc. Matus Knoblich CEO Med-Stat & Glo-Med Networks Mark Kolb Partner Tech Council Ventures Todd Kornfeld Partner McDermott Will & Emery, LLP Kristen Kosofsky Senior Managing Director Hercules Capital Kevin Kovaleski Strategic Alliance Management Lead Tevogen Bio, Inc. Timothy Kowalski Director, Pharma Drug Discovery Merck Animal Health Brent Kozlowski Business Development Manager Commercial Furniture Interiors Lawrence Krampf CEO V & L Ventures, LLC Daniella Kranjac Founding Partner Dynamk Capital Pallavi Krishnarao Academic Scholar Baylor College of Medicine Karen Krumeich Chief Financial Officer Kazia Therapeutics Limited Andy Kuhn Sr. Project Officer, Strategic Sector Development New Jersey Economic Development Authority (NJEDA) Kris Kuhner Strategic Portfolio Executive Partner PPD, Part of Thermo Fisher Scientific John Kulp Director, Business Development EVRYS Bio Patrick Kumm Partner Atinum Investment Ashim Lakhpat Vice President, Operation and Resourcing/Partner Circular Edge Andrew Lam Principal, Private Equity Ally Bridge Group Kendricks Lao Project Coordinator TCG GreenChem, Inc. Pablo Lapuerta CEO 4M Therapeutics, Inc. Sebastien Latapie Principal Dynamk Capital Andrew Latham Executive Director, Enabling Technologies, BD &L Merck & Co., Inc. Philip Laut Vice President, Biopharma Nanome, Inc. Wendy Lazarus Principal WML Public Affairs Guy Le Houillier General Manager, DTNA Domain Therapeutics Emer Leahy President & CEO PsychoGenics, Inc. Gary Lee Executive Director, Corporate Development Amicus Therapeutics, Inc. Alan Leeds Partner Morgan Lewis ATTENDEE LIST
45 Name Job Title Company Tom Leeker Chief Client Officer Aspirant Susan Levinson Founder & Chief Executive Officer BioAegis Therapeutics, Inc. Jack Levitt Co-Founder & Principal LeaderStrong Will Lewis Chair & CEO Insmed Victoria Liang Vice President, US Central Head Region, Biotech Operations PPD, part of Thermo Fisher Scientific Amy Liao CEO Couragene, Inc. Mike Liccardo Vice President Corp. Dev. & Chief Financial Officer; LP Strawberry Creek Ventures ShareVault Bob Linke President & CEO Osmol Therapeutics, Inc. Stash Lisowski Director, Business Development BDO USA, LLP Xuan Liu Associate Professor New Jersey Institute of Technology Chris Lloyd Industry Executive J.P. Morgan Chase Bank, NA Anthony Londino Founder & President Med-Con Technologies Gary Lynch Managing Partner Uncertainty Advantage Corp. Denise Machado Executive Director, Member Operations BioNJ Ivor Macleod Chief Financial Officer Scynexis, Inc. Janice Mahlmann CEO & CIO August eTech Gene Mancino Partner Mancino Burfield Edgerton Jason Mancivalano Executive Director, Asset & Wealth Management J.P. Morgan Chase Bank, NA Viraj Mane Co-Founder & Chief Scientific Officer Lactiga Cheryl Marchese Founder & CEO 325 Aashritha Marepalli Business Development Sannova Jennifer Marion Director, Client Engagement Center for Breakthrough Medicines Edward Marks Manager, Investments & Business Development TrialSpark Adam Marshall Partner RSM US, LLP Alain Martin CEO EmphyCorp, Inc. Michelle Martinez Product Officer, Venture Programs New Jersey Economic Development Authority (NJEDA) Amanda Maydan Vice President, Multi National J.P. Morgan Chase Bank, NA Elliot Maza General Manager Aspargo Laboratories, Inc. Dean McAlister Executive Vice President, Biotech Inizio Health Meaghan McAuliffe Associate, Healthcare Services J.P. Morgan Chase Bank, NA Margaret McCann Account Executive Medix Kathryn McDonough Managing Director, Industry Executive JP Morgan Chase Bank, NA Evan McGillin Associate Morgan Lewis Tagg McGurrin President & Chief Business Offcier Neumentum, Inc. Kevin McMonagle Partner, Finance & Accounting Outsourcing RSM US, LLP Jack McNeilly Investment Analyst Boston Millennia Partners Betsy McNeilly Executive Director, Financial Advisor Morgan Stanley Rik Mehta Co-Founder Lactiga, Inc. ATTENDEE LIST
46 Name Job Title Company Ketan Mehta Search & Evaluation Lead, Hospital & Vaccines, BD Pfizer Vishal Mehta CEO Ubuntu Research, Inc. Innes Meldrum President & CEO Reset Pharma Mary Mettias Director, NP BD Solid Tumors Janssen Pharmaceuticals Ernest Meyer Life Sciences Recruiter/ Sales trainee Medix Hany Michail Venture Partner BioAdvance Francois-Thomas Michaud CEO Feldan Therapeutics Randy Milby CEO Hillstream BioPharma, Inc. Robert Millar President & Director EmphyCorp, Inc. Mathias Miller Business Development Manager New Jersey Innovation Institute Haresh Mirchandani Vice President, BD GPH Rare Disease Novel Therapies Johnson & Johnson (Janssen) Piyush Modak Vice President, Research & Development Endomedix, Inc. Hasan Mohammad Business Development Manager Control Associates, Inc. Kara Moore Sector Lead, Life Sciences New Jersey Economic Development Authority (NJEDA) Katherine Mullen Analyst J.P. Morgan Chase Bank, NA Lauren Murdza Partner DLA Piper, LLP Justin Murray Director, Partnerships TechUnited: NJ Jack Mycka Vice President, PRMA & Emerging Biotech Commercialization MME, an Indegene PRMA Business Carolyn Myers Principal BioEnsemble, LLC Evan Myrianthopoulos Senior Managing Director Alliance Global Partners Kathy Naasz Vice President, Strategic Partnerships New Jersey Innovation Institute Dominik Naczynski Sr. Vice President Boxer Capital Siva Nadarajah President & Co-Founder JOGO Health, Inc. Yuna Nakayasu MPH/MBA Student Johns Hopkins University Akihiro Nanri Sr. Manager, International Business Development CMIC Holdings Co., Ltd. Jon Napoli Account Executive ShareVault Jayanthi Narasimhan Founder & CEO WatchRx, Inc. Alexander Natanzon Chief Technology Officer & Chief Operating Officer OsseoPrint 3D Kimberly Nearing Venture Partner BVCF Management, Ltd. Eric Neily Market Development Manager Kimberly-Clark Robert Neusner Chief Operating & Business Officer BMI OrganBank Thien Nguyen Associate Xontogeny Shawn Nicholas Business Development Director Labcorp Drug Development (Fortrea) Nicolas Nicolaou Board Member Promed Bioscience Steven Niewiadomski Senior Manager Marcum, LLP Simon Nynens Investor, Mentor, CEO Coach NYNENS, LLC Dennis O'Dowd CEO AGelity Biomechanics Corporation Kristine O'Keefe Executive Director, Private Bank J.P. Morgan Chase Bank, NA Nancy Ondovik Sr. Director, New Company Creation Johnson & Johnson Innovation ATTENDEE LIST
47 Name Job Title Company Laura Osorno Intellectual Property Manager New Jersey Institute of Technology (NJIT) Onyema Osuagwu CEO BioNanoTech Thierry Page Executive Vice President & Chief Operating Officer Starpax Biopharma, Inc. Joon Pak Associate Director, Business Development Lonza Biologics Jayen Palekar Therapeutic Area Lead Janssen Pharmaceuticals, Inc. Gene Palermo Project Officer, Strategic Sector Development New Jersey Economic Development Authority (NJEDA) Michael Paranich Director, Operations August eTech Mitul Parikh MBA Student Rutgers Business School Kirthika Parmeswaran Founder & CEO Vital Start Health Luca Parolari Sr. Associate DCVC Bio Shobha Parthasarathi Advisor, External Innovation Xontogeny Murali Parthasarathy Vice President, Business Development & Commercialization AMPEL BioSolutions, LLC Parth Patel IT Support Technician August eTech Sona Patel Associate Professor Seton Hall University Shyam Pattabiraman Chief Financial Officer Jubilant Therapeutics, Inc. John Pena CEO Sonder Research X Jianya Peng Research Scientist NemaGen Discoveries Andrew Peranick Director, Business Development & Corporate Strategy Adiso Therapeutics, Inc. Sabina Perchik Director, Transactions, BD & Licensiing Johnson & Johnson (Janssen) Kate Pestrichelli Vice President, Project Management The FlexPro Group Melanie Piperno Director CFGI, LLC Emad Piracha Senior Associate Signet Healthcare Partners Paul Piro Sr. Mgr., Talent Acquisiton, Cell Therapy Devel. Bristol Myers Squibb Michael Poisel Executive Director, PCI Ventures University of Pennsylvania Aarthi Prakash Academic Scholar Rutgers University School of Business Nikhil Puri Managing Director Signet Healthcare Partners Mohammed Quadri Vice President, Strategy for Academics, Research & Innov. Hackensack Meridian Health Rashanique Quarels Assistant Professor, College of Science & Mathmatics Rowan University Bill Ragatz President & CEO Sentrimed Ravi Raghunathan Partner CohnReznick, LLP Emilio Ragosa Partner DLA Piper, LLP Karthik Ramachandran Chief Operating Officer & Co-Founder Likarda Kalpana Ramakrishnan Senior Manager, Business Development Pharming Suman Rao Associate Lumira Ventures Joseph Rayman Chief Scientific Officer Omnitia Therapeutics Elliot Reiff Chief Financial Officer SciMar ONE, Inc. James Reynolds Principal Marcum, LLP Varvara Reznichenko Business Development Representative Circular Edge ATTENDEE LIST
48 Name Job Title Company Jamie Richardson Business Development Associate 1315 Capital John Ritter Director, Office of Tech Licensing & Intellect Prop Princeton University Blake Roberts Partner Centri Business Consulting Michelle Roemer-Schoen Event Manager Princeton Innovation Center BioLabs Tricia Roman Chief Operating Officer & Director of Client Services 325 Rachel Rondinelli Director, Research & Academic Partnership Johnson & Johnson World Headquarters Ren Roome Partner Boston Millennia Partners Kristin Roosevelt Industry Director Fisher Scientific Company, LLC Heather Rose Vice President, Technology Licensing & Startups Jefferson Health Jack Rosenberg Investments & Business Deveopment TrialSpark Philip Ross Managing Director J.P. Morgan Chase Bank, NA Wayne Rowe Academic Partnerships Program Lead Sanofi Elizabeth Rowley Director, Operations Princeton Innovation Center BioLabs Najur Runganadhan CEO See-Me, Inc. Michael Russo Partner CFGI Richard Russo President & CEO Endomedix, Inc. Alicia Russo Partner Venable Winnie Sabbat Managing Partner Sabacica Capital Zohaib Saeed Director Acquisitons Janssen R&D US Marzieh Saeedi Software Engineer Robossis, Inc. Larry Samilow Co-Founder & Managing Director Verve Group Consulting Matt Sampson Audit Manager WithumSmith+Brown, PC Josh Sanders Vice President, Global IP, Litigation & Employment Amneal Pharmaceuticals David Santangelo Partner McDermott Will & Emery, LLP George Santo Vice President, Life Sciences J.P. Morgan Chase Bank, NA Kathleen Sanzo Partner Morgan Lewis Adriann Sax President & CEO Vetigenics, LLC Mary Schaheen President Prevail Partners Kim Schaller Student Rutgers Business School Peggy Schell Talent Service & Public Policy Assistant BioNJ Michael Schetlick Managing Director Centri Business Consulting Suzann Schiller Executive Vice President, Strategic Collaborations Lumanity Ryan Schipke Director, Transacions CVMR Janssen R&D US Andy Schluter Account Executive Medix David Schwartz Partner Morgan Lewis Andrew Scott Managing Director, Investment Banking ThinkEquity, LLC John Seman CEO Canget BioTekpharma Squire Servance Managing Partner Syridex Bio Vicki Seyfert-Margolis Founder & CEO RespondHealth ATTENDEE LIST